This article was downloaded by:


On: 26 January 2011

Access details: Access Details: Free Access

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Synthesis of 2',3'-Dideoxy-2'-Fluoro-l-*threo*-Pentofuranosyl Nucleosides as Potential Antiviral Agents

Socrates C. H. Cavalcanti^a; Yuejun Xiang^a; M. Gary Newton^a; Raymond F. Schinazi^b; Yung-Chi Cheng^c; Chung K. Chu^a

^a Center for Drug Discovery, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy and Department of Chemistry, The University of Georgia, Athens, Georgia ^b Department of Pediatrics, Emory University School of Medicine Veterans Affairs Medical Center Decatur, Georgia ^c Department of Pharmacology, Yale School of Medicine, New Haven, Connecticut, USA

To cite this Article Cavalcanti, Socrates C. H. , Xiang, Yuejun , Newton, M. Gary , Schinazi, Raymond F. , Cheng, Yung-Chi and Chu, Chung K.(1999) 'Synthesis of 2',3'-Dideoxy-2'-Fluoro-l-threo-Pentofuranosyl Nucleosides as Potential Antiviral Agents', Nucleosides, Nucleotides and Nucleic Acids, 18: 10, 2233 — 2252

To link to this Article: DOI: 10.1080/07328319908044878 URL: http://dx.doi.org/10.1080/07328319908044878

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF 2',3'-DIDEOXY-2'-FLUORO-L-threo-PENTOFURANOSYL NUCLEOSIDES AS POTENTIAL ANTIVIRAL AGENTS

Sócrates C. H. Cavalcanti, Yuejun Xiang, M. Gary Newton, Raymond F. Schinazi, Yung-Chi Cheng, and Chung K. Chu

[†]Center for Drug Discovery, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy and Department of Chemistry, The University of Georgia, Athens, Georgia 30602; *Department of Pediatrics, Emory University School of Medicine Neterans Affairs Medical Center Decatur, Georgia 30033; and

[‡]Department of Pharmacology, Yale School of Medicine, New Haven, Connecticut, 06510 USA.

ABSTRACT: A series of 2',3'-dideoxy-2'-fluoro-L-*threo*-pentofuranosyl nucleosides has been synthesized as potential antiviral agents. The synthesized compounds were evaluated against HIV-1, HBV, HSV-1, and HSV-2. Among the synthesized analogues, only the cytosine derivative showed moderate antiviral activity against HIV and HBV.

Little attention had been given to unnatural L-nucleosides until the finding that (-)-\(\beta\cdot\)-1-1-[(2-hydroxymethyl)oxathiolan-5-yl]cytosine (3TC)^{1,2} and (-)-β-L-2',3'-dideoxy-5-fluoro-2'thiacytidine (FTC)^{3, 4} were found to be more active and less toxic than their (+)-D-isomers^{4, 5} against HIV-1 and hepatitis B virus (HBV).^{6,7} Biochemically, some L-nucleosides are substrates for cellular kinases8,9 and also have greater stability for catabolizing enzymes such as cytidine and adenosine deaminase, 10 thereby, providing higher anti-HIV and anti-HBV activities. In addition to 3TC and FTC, (-)-β-L-dioxolanecytosine [(-)-OddC], 11, 12 2'-fluoro-5-methyl-βarabinofuranosyl uridine (L-FMAU), ^{13, 14} 2', 3'-dideoxy-β-L-cytosine (L-ddC), ^{4, 7} and 2', 3'dideoxy-β-L-5-fluorocytosine (L-FddC)^{15, 16} have demonstrated potent anti-HIV and anti-HBV activities. As 9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl)adenine (2'-F-Ara-ddA), 17 and 9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl)cytosine (2'-F-Ara-ddC)¹⁸ have shown to be potent against HIV, it was of interest to synthesize the corresponding L-nucleosides. In our preliminary studies we found that the 9-(2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine derivative was moderately active against HIV and HBV.¹⁹ Therefore, herein we wish to report the comprehensive structure-activity relationships of 2',3'-dideoxy-2'-fluoro-L-threo-pentofuranosyl nucleosides.

CHEMISTRY

Synthesis of the key intermediate 7 was accomplished by a similar procedure reported for the preparation of D-isomer (Scheme I).²⁰ Compound 1 was synthesized according to the procedure published by Ma *et al.*²¹ The reaction of 1 under Wolff-Kishner conditions gave the 3-deoxy derivative 4.²² The tosyl hydrazone derivative 2 was prepared by the reaction of 1 with *p*-toluenesulfonylhydrazide in EtOH in 71% yield. Reduction of 2 with NaCNBH₃ in methanol at pH 3 gave the reduced compound 3, which was refluxed with NaOAc.3H₂O in ethanol to obtain the deoxygenated compound 4 in 69% yield. Selective deprotection of the isopropylidene of compound 4 using 80% acetic acid at 100 °C for 4 h gave the diol 5 in 80% yield. Since the direct condensation of difluoro sugar 6 with a base gave low yield,²³ the compound 6 was brominated with 45% HBr/HOAc to the key intermediate 7, which was condensed with bases. Once 7 is unstable, it was synthesized before the condensation step and readily used.

Pyrimidine nucleosides were prepared by the Hilbert-Johnson method (cytosine and thymine derivatives) or Vorbrüggen method (uracil derivatives) using TMSOTf as catalyst. The 5'-benzoylated uracil derivatives 8-17 were synthesized by condensation of 7 with silylated 5-substituted uracil bases in dichloroethane (DCE) and catalytic amounts of TMSOTf to give an α , β -mixture, which was purified by silica gel column chromatography followed by separation by fractional recrystallization (uracil and fluorouracil). The anomers were individually deprotected by methanolic ammonia to afford the final uracil derivatives 25-34 (Scheme I). The condensation of 7 with silylated cytosine in dry CH₃CN gave the protected cytosine 18, which was purified by silica gel column chromatography. Higher yields were obtained when DCE was used, instead of CH₃CN, for the preparation of 5-substituted cytosine derivatives 19-23. Compounds 18-23 were then treated with methanolic ammonia to give the nucleoside derivatives 35-40 (Scheme I). Synthesis of the thymine derivative was accomplished by the condensation of 7 with silylated thymine in CH₃CN, followed by deprotection in methanolic ammonia yielding 41 as white crystals.

In order to prepare purine derivatives, silylated 6-chloropurine was condensed with 7 in the presence of TMSOTf to give an α , β mixture of 42 and 43, which was separated by silica gel column chromatography (Scheme I). The inosine derivatives 46 and 47 were synthesized by refluxing compounds 42 and 43 with NaOMe and mercaptoethanol in methanol. The α - and β -chloropurine derivatives were also converted to adenine derivatives 48 and 49 by treatment with methanolic ammonia at 100 °C. Treatment of 42 and 43 with methylamine in methanol at 90 °C yielded N^6 -methyladenine analogues 50 and 51.


The key intermediate 7 was also used for the synthesis of the guanosine derivative. Condensation of 7 with 2-isobutyrylamino-6-chloropurine in the presence of TMSOTf gave an α , β -mixture 44 and 45, which was readily separated by silica gel column chromatography. The guanosine derivatives were obtained by refluxing compounds 44 and 45 in similar conditions as for the inosine derivatives, to afford the β -isomer 52 as a white foam and the α -isomer 53 as white crystals.

The structure and stereochemistry of 5-fluoro-1-(5-*O*-benzoyl-2,3-dideoxy-2-fluoro-β-Lthreo-pentofuranosyl)cytosine (**19**) was also confirmed by X-ray crystallography (Figure I).²⁵

ANTIVIRAL ACTIVITY

The synthesized nucleosides 25-41 and 46-53 were evaluated against HIV-1, HBV, HSV-1, and HSV-2. The antiviral activity was expressed by the concentration (μ M) that inhibits

SCHEME 1



i) NH₂NHTs, EtOH; ii) NaCNBH₃, MeOH; iii) NaOAc·3H₂O, EtOH; iv) OHAc (80 %, 100 °C); v) DAST. CH₂Cl₂; vi) 45 % HBr/OHAc, CH₂Cl₂; vii) Silylated base; viii) Deprotection.

50% of viral replication (Table I). Among these analogues, only the cytosine analogue 35 exhibited moderate anti-HIV-1 and anti-HBV activity in vitro with EC $_{50}$ values of 16.2 and 4.0 μ M in PBM cells and 2.2.15 cells, respectively. Other derivatives show neither significant antiviral activity nor cytotoxicity.

EXPERIMENTAL

Melting points were determined on a Mel-temp II laboratory device and are uncorrected. Nuclear magnetic resonance spectra were recorded on a Bruker 250 and AMX 400 MHz




Figure I. Ortep plot of compound 19.

spectrometers with tetramethylsilane as the internal reference; chemical shifts are reported in parts per million (δ), and the signals are described as s (singlet), d (doublet), t (triplet), q (quartet), bs (broad singlet), dm (doublet of multiplet), and m (multiplet). UV spectra were obtained on a Beckman DU 650 spectrophotometer. Optical rotations were measured on a Jasco DIP-370 digital polarimeter. Low and high resolution mass spectra were obtained by Dr. Dennis R. Phillips and Dr. Michael Bartlett on a Ribermag R10-10C and a Micromass Inc. Autospec High Resolution double focusing sector (EBE) MS spectrometers. Infrared spectra were recorded on a Nicolet 510 FT-IR spectrometer. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA. All reactions were monitored using thin layer chromatography on Analtech, 200 mm silica gel GF plates.

5-O-Benzoyl-1,2-O-isopropylidene-p-toluenesulfonylhydrazone-α-L-erythropentofurano-3-ulose (2). A solution of 1 (30.00 g, 102.00 mmol) and p-toluenesulfonylhydrazide (21.00 g, 112.00 mmol) in absolute ethanol (150 mL) was refluxed for 2 h and then cooled to 0 °C. The white crystalline needles were filtered and washed with diethyl ether to give pure product 2 (33.50 g, 71%). mp 174-175 °C; IR (KBr) 1722, 1070 cm⁻¹; ¹H NMR (CDCl₃): δ 11.19 (s, 1H, NH, D_2O exch.); 7.70-7.05 (m, 9H, Ar-H); 5.98 (d, 1H, H-1, J = 4.6 Hz); 5.05-5.00 (m, 2H, H-2 and H-4); 4.68-4.28 (m, 2H, H-5); 2.35 (s, 3H, CH₃-Ar); 1.39 (s, 3H, CH₃); 1.18 (s, 3H, CH₂); 13 C NMR (DMSO- d_2) δ 165.5, 154.6, 143.6, 135.8, 133.7, 129.5, 129.4, 129.4, 128.9, 127.4, 112.9, 104.7, 76.5, 73.3, 65.7, 27.5, 27.3, 21.2; Anal. Calcd. for C₂₂H₂₄N₂O₂S: C, 57.38; H, 5.28; N, 6.08. Found: C, 57.49; H, 5.26; N, 6.06. 5-O-Benzoyl-3-deoxy-1,2-O-isopropylidene-3-p-toluenosulfonylhydrazino-α-Lribofuranose (3). To a stirred solution of 2 (33.50 g, 72.80 mmol) in a mixture of THF and MeOH (400 mL, 1:1) was added a trace of methyl orange and sodium cyanoborohydride (4.41 g, 70.00 mmol). Saturated methanolic HCl was added dropwise keeping the color of the solution red yellow transition point during all the reaction time (pH = 3). The mixture was stirred at rt for 1 h. A second portion of NaCNBH₃ (2.52 g, 40.00 mmol) was added followed by dropwise addition of methanolic HCl to maintain pH at 3. The solution was stirred at rt for another hour, then neutralized with sat NaHCO3, and concentrated to dryness. The residue was dissolved in H2O (150 mL) and extracted with CH₂CI₂ (3 X 150 mL). The organic layer was washed with brine (3

TABLE I. Antiviral activities and cytotoxicities of 2',3'-dideoxy-2'-fluoro-L-threo-pentofuranosyl nucleosides.

Number	HBV EC ₅₀ (μM) (2.2.15)	HIV-1 EC ₅₀ (μΜ) (PBM)	HSV (I+II) IC ₅₀ (μM)	Cytotoxicity		
				IC ₅₀ (µM) PBM	IC ₅₀ (μM) CEM	IC ₅₀ (µM) Vero
25	>10	155.0	>100	>100	>100	>100
26	>10	>100	>100	>100	>100	>100
27	>50	>100	>100	>100	>100	>100
28	>10	>100	>100	>100	>100	>100
29	>50	>100	>100	>100	>100	>100
30	>100	>100	>100	>100	>100	>100
31	>50	>100	>100	>100	>100	>100
32	>50	>100	>100	>100	>100	>100
33	>50	>100	>51	>100	>100	>100
34	>50	>100	>40	>100	61.1	>100
35	4.0	16.4	ND	>100	>100	>100
36	>10	48.0	>100	>100	>100	>100
37	>10	>100	>100	>100	>100	>100
38	>10	>100	>100	>100	>100	>100
39	>100	>100	>100	>100	>100	>100
40	>50	>100	>100	>100	>100	>100
41	>10	190	>100	>100	>100	>100
46	>10	>100	>100	>100	>100	>100
47	>10	>100	>100	>100	>100	>100
48	>10	>100	ND	>100	>100	>100
49	>100	ND*	>100	>100	>100	ND
50	>10	>100	>100	>100	>100	>100
51	>10	>100	>100	>100	>100	>100
52	ND	>100	>100	>100	>100	>100
53	>10	>100	>100	ND	>100	>100
AZT	>100	0.004	ND	>100	14.3	29.0

Not determined

X 100 mL), dried over Na₂SO₄ and the solvent was removed under reduced pressure to obtain the product **3** as a white solid, which was crystallized in methanol (31.50 g, 94%). mp 148-150 °C; IR (KBr) 1691, 1072 cm⁻¹; ¹H NMR (CDCl₃): δ 11.18 (s, 1H, NH-Ar, D₂O exch.); 9.98 (s, 1H, NH, D₂O exch.); 7.74-7.06 (m, 9H, Ar-H); 5.99 (d, 1H, H-1, J = 3.7 Hz); 5.36-5.35 (m, 1H, H-2); 5.07 (s, 1H, H-4); 4.38-4.34 and 4.08-4.04 (m, 2H, H-5); 3.23-3.20 (m, 1H, H-3); 2.38 (s, 3H, CH₃-Ar); 2.09 (s, 3H, CH₃); 1.79 (s, 3H, CH₃); ¹³C NMR (DMSO- d_6) δ 165.5, 143.3, 135.8, 133.7, 129.7, 129.5, 129.4, 128.9, 127.6, 127.4, 112.9, 104.6, 76.5, 73.3, 65.7, 27.5, 27.3, 25.1; *Anal.* Calcd. for C₂₂H₂₆N₂O₇S: C, 57.13; H, 5.67; N, 6.06. Found: C, 57.01; H, 5.61; N, 6.05.

5-*O*-Benzoyl-3-deoxy-1,2-*O*-isopropylidene- α -L-*erythro*-pentofuranose (4). A mixture of 3 (31.10 g, 65.00 mmol) and sodium acetate trihydrate (35.50 g, 264.00 mmol) in absolute ethanol (700 mL) was refluxed for 1 h. The solvent was removed under reduced pressure, and the residue was taken up in EtOAc (300 mL), washed with brine (3 X 100 mL) and dried over Na₂SO₄. After concentration, the crude mixture was purified by silica gel column chromatography (20% EtOAc/hexanes) to give pure compound 4 as a clear syrup (13.00 g, 69%). $[\alpha]_D^{25}$ +10.5° (c 0.50, MeOH); IR (neat) 1720, 1068 cm⁻¹; ¹H NMR (CDCl₃): δ 8.05 (d, 2H, Ar-

H, J = 8.3 Hz); 7.56 (t, 1H, Ar-H, J = 7.1 Hz); 7.43 (t, 2H, Ar-H, J = 7.5 Hz); 5.85 (d, 1H, H-1, J = 3.6 Hz); 4.76 (t, 1H, H-2, J = 4.2 Hz); 4.59-4.53 (m, 1H, H-4); 4.59-4.53 (m) and 4.40 (dd, 2H, H-5, J = 6.0 and 12.2 Hz); 2.19 (dd, 1H, H-3, J = 6.1 and 13.3 Hz) and 1.80 (m, 1H, H-3); 1.51 (s, 3H, CH₃); 1.31 (s, 3H, CH₃); 13 C NMR (CDCl₃) δ 166.6, 133.4, 130.1, 130.0, 128.7, 111.6, 106.0, 80.6, 76.1, 65.6, 35.7, 27.1, 26.4; *Anal.* Calcd. for C₁₅H₁₈O₅: C, 64.73; H, 6.52. Found: C, 64.48; H, 6.54.

- **5-***O*-**Benzoyl-3-deoxy-L**-*erythro*-**pentose** (**5**). The mixture of **4** (10.00 g, 42.00 mmol) in 50 mL 80% HOAc was heated at 100 °C for 4 h. The solvent was removed under reduced pressure and coevaporated with toluene (2 X 30 mL). The syrup was purified by silica gel column chromatography (10% MeOH/CHCl₃) to give **5** as a white solid (6.80 g, 28.00 mmol, 68%), which was recrystallized from EtOAc and hexanes. mp 73-74 °C; IR (KBr) 3383, 3254, 1711, 1080 cm⁻¹; ¹H NMR (DMSO- d_6): δ 7.99 (d, 2H, Ar-H, J = 7.2 Hz); 7.64 (t, 1H, Ar-H, J = 6.7 Hz); 7.52 (d, 2H, Ar-H, J = 7.1 Hz); 6.17 (d, 1H, H-1, J = 4.5 Hz); 5.05 (bs, 2H, 3-OH, 2-OH, D₂O exch.); 4.33-4.22 (m, 3H, H-4 and H-5); 3.98-3.96 (m, 1H, H-2); 1.96-1.83 (m, 2H, H-3); ¹³C NMR (DMSO- d_6) δ 166.0, 133.7, 130.0, 129.5, 129.0, 103.2, 76.1, 75.5, 68.5, 34.3; *Anal.* Calcd. for C₁₂H₁₄O₅: C, 60.50; H, 5.92. Found: C, 60.43; H, 5.90.
- **5-***O*-**Benzoyl-2,3-dideoxy-1,2-difluoro-**α-**L**-*threo*-**pentofuranosyl** (6). To a solution of the sugar **5** (2.00 g, 8.80 mmol) in anhydrous CH₂Cl₂ (50 mL), DAST (6 mL, 45.40 mmol) was slowly added at -20 °C, and the reaction mixture was stirred at rt for 10 h, then the reaction mixture was cooled to 0 °C and quenched with methanol. The solvent was evaporated to dryness and the residue was purified by silica gel column chromatography (10% EtOAc/hexanes) to yield **6** (0.95 g, 46%) as a clear oil. $[\alpha]_D^{25}$ -46.8° (c 0.61, MeOH); IR(neat) 1724 cm⁻¹; ¹H NMR (CDCl₃): δ 8.07 (d, 2H, Ar-H, J = 7.3 Hz); 7.57 (t, 1H, Ar-H, J = 5.3 Hz); 7.43 (t, 2H, Ar-H, J = 7.6 Hz); 5.94 (dd, 1H, H-1, J = 5.2 and 59.5 Hz); 5.16 (ddd, 1H, H-2, J = 51.8, 2.4 and 5.1 Hz); 4.78 (m, 1H, H-4); 4.51-4.35 (m, 2H, H-5); 2.22-2.02 and 2.62-2.43 (m, 2H, H-3); ¹³C NMR (CDCl₃) δ 166.7, 133.6, 130.1, 130.0, 120.8, 112.7 (dd, J = 220.8 and 34.2 Hz), 94.15 (dd, J = 180.0 and 40.7 Hz), 79.2, 66.2, 31.5 (d, J = 20.5 Hz); *Anal.* Calcd. for C₁₂H₁₂F₂O₃: C, 59.50; H, 4.99. Found: C, 59.33; H, 4.92.
- 5-O-Benzoyl-1-bromo-2,3-dideoxy-2-fluoro- α -L-threo-pentofuranosyl (7). To a solution of 6 (0.36 g, 1.59 mmol) in CH₂Cl₂ (10.4 mL), was added 45% HBr/HOAc (1.73 mL, 9.61 mmol). The reaction mixture was stirred at rt for 1 h. After evaporation of the solvent and co-evaporation with toluene (2 X 26 mL), the crude mixture obtained was not purified and used directly for the next reaction.

General procedure for condensation of bromide 7 with 5-substituted uracils. A mixture of silylated uracil (2.10 g, 18.73 mmol), hexamethyldisilazane (HMDS) and a catalytic amount of $(NH_4)_2SO_4$ was refluxed for 4 h. The clear solution obtained was concentrated to dryness *in vacuo*. The residue of the brominated sugar 7, which was prepared from bromination of 6 (1.34 g, 5.88 mmol) was taken up into dry DCE (35 mL) and added to the base, followed by addition of trimethylsilyl trifluoromethanesulfonate (TMSOTf, 1.27 mL, 6.57 mmol) at 0 °C. Then the reaction mixture was refluxed for 20 h under nitrogen. After completion, the reaction mixture was washed with sat NaHCO₃ solution (100 mL), dried (Na₂SO₄), filtered through Celite pad and concentrated *in vacuo*. The crude mixture was purified by flash silica gel column chromatography (50% EtOAc/hexanes) to yield a mixture of α and β (0.73 g, 37%), which were separated by fractional recrystallization in DCE to afford 8 (0.24 g) and 9 (0.48 g).

1-(5-O-Benzoyl-2,3-dideoxy-2-fluoro-(β and α)-L-threo-pentofuranosyl)uracil (8

and 9). 8: mp 158-159 °C; $[\alpha]_D^{25}$ -122.5° (c 0.30, MeOH); UV (MeOH) λ_{max} 257.0 nm; IR (KBr) 3105, 3013, 1724, 1709, 1687, 1076 cm⁻¹; ¹H NMR (DMSO- d_{δ}): δ 8.89 (bs. 1H. NH): 8.07 (d, 2H, Ar-H, J = 7.7 Hz); 7.63-7.45 (m, 4H, Ar-H and H-5); 6.07 (dd, 1H, H-1'. J = 19.8and 2.6 Hz); 5.71 (d, 1H, H-6, J = 8.1 Hz); 5.29 (d, 1H, H-2', J = 53.5 Hz); 4.60-4.51 (m. 3H. H-4' and H-5'); 2.71-2.32 (m, 2H, H-3'); 13 C NMR (DMSO d_6) δ 165.0, 163.2, 149.8, 141.2. 133.8, 130.1, 129.7, 128.9, 102.2, 90.8 (d, J = 188.0 Hz), 86.7 (d, J = 16.1 Hz), 75.7, 65.9. 33.9 (d, J = 21.0 Hz); Anal. Calcd. for $C_{16}H_{15}FN_2O_5$: C, 57.51; H, 4.48; N, 8.38. Found: C. 57.32; H, 4.55; N, 8.43. **9**: mp 194-195 °C; $[\alpha]_D^{25}$ +41.1° (c 0.19, MeOH); UV (MeOH) λ_{max} 257.0 nm; IR (KBr) 3049, 1718, 1676, 1066 cm⁻¹; ¹H NMR (DMSO-d_δ): δ 11.40 (bs. 1H. NH. D_2O exch.); 8.01 (d, 2H, Ar-H, J = 7.8 Hz); 7.68 (t, 1H, Ar-H, J = 7.2 Hz); 7.60 (d, 1H, H-5. J= 8.1 Hz); 7.55 (t, 2H, Ar-H, J = 7.7 Hz); 5.99 (d, 1H, H-6, J = 16.3 Hz); 5.59 (d. 1H, H-1'. J=8.1 Hz); 5.51 (d, 1H, H-2', J = 52.9 Hz); 4.96-4.95 (m, 1H, H-4'); 4.42-4.35 (m. 2H, H-5'); 2.71-2.15 (m, 2H, H-3'); ¹³C NMR (DMSO d_6) δ 165.9, 163.7, 150.7, 141.5, 133.8, 129.7. 129.6, 129.1, 101.8, 96.6 (d, J = 178.4 Hz), 92.5 (d, J = 36.4 Hz), 80.0, 66.7, 32.9 (d, J = 36.4 Hz) 20.4 Hz); Anal. Calcd. for C₁₆H₁₅FN₂O₅: C, 57.51; H, 4.48; N, 8.38. Found: C, 57.49; H. 4.51; N, 8.45.

5-Fluoro-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-(β and α)-L-threopentofuranosyl)uracil (10 and 11). 5-Fluorouracil (1.00 g, 7.68 mmol), 7 (0.55 g. 2.41 mmol), and TMSOTf (0.5 mL, 2.60 mmol) were reacted for 16 h to give a mixture of 10 and 11. which was purified by flash silica gel column chromatography (50% EtOAc/hexanes) and separated by fractional recrystallization in EtOAc/MeOH (4:1) to yield 10 (0.12 g, 14%), and 11 (0.26 g, 30%) as white solids. **10**: mp 154-156 °C; $[\alpha]_D^{25}$ -91.9° (c 0.29, EtOAc); UV (EtOAc) λ_{max} 263.5 nm; IR (KBr) 1720, 1670, 1072 cm⁻¹; ¹H NMR (DMSO- d_6): δ 12.01 (s, 1H, NH, D,O exch.); 7.98 (d, 2H, Ar-H, J = 8.3 Hz); 7.80 (dd, 1H, H-6, J = 7.0 and 1.7 Hz); 7.66 (t. 1H. Ar-H, J = 7.3 Hz); 7.52 (t, 2H, Ar-H, J = 7.6 Hz); 6.04 (d, 1H, H-1', J = 17.5 Hz); 5.30 (dd, 1H, H-2', J = 54.6 and 2.7 Hz); 4.58-4.47 (m, 3H, H-4' and H-5'); 2.76-2.60 and 2.26-2.15 (m, 2H, H-3'); 13 C NMR (DMSO d_c) δ 166.0, 157.2 (d, J = 27.4 Hz), 149.0, 139.8 (d, J = 230.3Hz), 133.9, 129.6, 129.5, 129.1, 125.7 (d, J = 34.6 Hz), 91.5 (d, J = 186.0 Hz), 85.6 (d, J = 186.0 Hz), 85.7 (d, J = 186.0 Hz), 85.7 (d, J = 186.0 Hz), 85.7 (d, J = 186.0 Hz), 85.6 (d, 14.6 Hz), 75.3, 66.1, 33.2 (d, J = 19.9 Hz); Anal. Calcd. for $C_{16}H_{14}F_2N_2O_5$: C, 54.57; H, 3.97; N, 7.95. Found: C, 54.50; H, 4.05; N, 7.92. 11: mp 190-191 °C; $[\alpha]_{D}^{25}$ +28.3° (c 0.39. EtOAc); UV (EtOAc) λ_{max} 265.0 nm; IR (KBr) 1732, 1707, 1682, 1074 cm⁻¹; ¹H NMR (DMSO d_6): δ 11.91 (s, 1H, NH, D₂O exch.); 7.99 (d, 2H, Ar-H, J = 8.3 Hz); 7.93 (d, 1H, H-6, J = 6.9Hz); 7.66 (t, 1H, Ar-H, J = 8.2 Hz); 7.53 (t, 2H, Ar-H, 7.8 Hz); 5.94 (d, 1H, H-1', J = 15.6Hz); 5.46 (dd, 1H, H-2', J = 52.7 and 5.1 Hz); 5.03-4.98 (m, 1H, H-4'); 4.39-4.30 (m, 2H, H-4'); 5'); 2.67-2.48 and 2.22-2.12 (m, 2H, H-3'); 13 C NMR (DMSO d_6) δ 171.3, 162.4 (d, J = 26.2Hz), 154.3, 145.0 (d, J = 230.6 Hz), 139.1, 134.9, 134.8, 134.4, 130.9 (d, J = 35.4 Hz), 96.8 (d, J = 185.0 Hz), 90.8 (d, J = 15.7 Hz), 80.5, 71.3, 38.4 (d, J = 20.0 Hz); Anal. Calcd. for $C_{16}H_{14}F_2N_2O_5$; C, 54.57; H, 3.97; N, 7.95. Found: C, 54.65; H, 4.03; N, 7.87. 5-Bromo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-(β and α)-L-threopentofuranosyl)uracil (12 and 13). 5-Bromouracil (1.00 g, 5.23 mmol), 7 (0.53 g, 2.32 mmol), and TMSOTf (0.5 mL, 2.60 mmol) were reacted for 16 h to give a mixture of 12 and 13. which was separated by flash silica gel column chromatography (50% EtOAc/hexanes) and recrystallized in EtOAc to afford 12 (0.15 g, 15%), and 13 (0.30 g, 31%) as white solids. 12: mp 122-124 °C; $[\alpha]_D^{25}$ -51.6° (c 0.33, EtOAc); UV (EtOAc) λ_{max} 273.5 nm; IR (KBr) 1718,1070

cm⁻¹; ¹H NMR (DMSO- d_6): δ 12.01 (s, 1H, NH, D₂O exch.); 8.00 (d, 2H, Ar-H, J = 8.1 Hz);

7.89 (s, 1H, H-6); 7.67 (t, 1H, Ar-H, J = 8.3 Hz); 7.53 (t, 2H, Ar-H, J = 7.6 Hz); 6.04 (dd, 1H, H-1', J = 19.3 and 2.9 Hz); 5.28 (d, 1H, H-2', J = 54.6 Hz); 4.57-4.50 (m, 3H, H-4' and H-5'): 2.77-2.61 and 2.29-2.17 (m, 2H, H-3'); 13 C NMR (DMSOd₆) δ 166.0, 159.3, 149.7, 140.5, 133.9, 129.7, 129.5, 129.1, 95.6, 91.5 (d, J = 185.8 Hz), 86.0 (d, J = 14.8 Hz), 75.5, 65.7, 33.1 (d, J = 20.1 Hz); Anal. Calcd. for $C_{16}H_{14}BrFN_2O_5$: C, 46.52; H, 3.38; N, 6.77. Found: C, 46.60; H, 3.44; N, 6.75. 13: mp 158-160 °C; $[\alpha]_D^{25}$ +12.9° (c 0.43, EtOAc); UV (EtOAc) λ_{max} 274.0 nm; IR (KBr) 1714, 1072 cm⁻¹; ¹H NMR (DMSO- d_6): δ 11.90 (s, 1H, NH, D,O exch.); 8.01 (d, 2H, Ar-H, J = 6.8 Hz); 7.98 (s, 1H, H-6); 7.66 (t, 1H, Ar-H, J = 7.5 Hz); 7.53 (t, 2H, Ar-H, J = 7.7 Hz); 5.94 (d, 1H, H-1', J = 16.4 Hz); 5.52 (dd, 1H, H-2', J = 53.0 and 5.3 Hz); 5.02-4.97 (m, 1H, H-4'); 4.40-4.30 (m, 2H, H-5'); 2.72-2.48 and 2.21-2.11 (m, 2H, H-3'); ¹³C NMR (DMSO d_6) δ 165.9, 159.7, 150.1, 141.0, 133.8, 129.7, 129.6, 129.1, 96.6 (d, J = 177.92Hz), 96.2, 93.1 (d, J = 38.4 Hz), 80.2, 66.7, 32.4 (d, J = 20.5 Hz); Anal. Calcd. for C₁₆H₁₄BrFN₂O₅: C, 46.52; H, 3.38; N, 6.77. Found: C, 46.48; H, 3.45; N, 6.77. 5-Iodo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-(β and α)-L-threopentofuranosyl)uracil (14 and 15). 5-Iodouracil (1.50 g, 6.30 mmol), 7 (1.12 g, 4.90 mmol), and TMSOTf (0.25 mL, 1.30 mmol) were reacted for 16 h to give a mixture of 14 and 15, which was separated by flash silica gel column chromatography (40% EtOAc/hexanes) and recrystallized in EtOAc to afford 14 (0.33 g, 14%), and 15 (0.39 g, 17%) as white solids. 14: mp 160-162 °C; $[\alpha]_D^{25}$ -23.0° (c 0.23, MeOH); UV (MeOH) λ_{max} 280.5 nm; IR (KBr) 1701, 1072 cm⁻¹; ¹H NMR (DMSO- d_s): δ 11.86 (s, 1H, NH, D₂O exch.); 8.03 (d, 2H, Ar-H, J = 9.3 Hz); 7.92 (s, 1H, H-6); 7.67 (t, 1H, Ar-H, J = 7.3 Hz); 7.54 (t, 2H, Ar-H, J = 7.7 Hz); 5.27 (d, 1H, H-2', J = 57.9 Hz); 6.02 (dd, 1H, H-1', J = 19.7 and 2.9 Hz); 4.57-4.49 (m, 3H, H-4' and H-5'); 2.77-2.62 and 2.28-2.17 (m, 2H, H-3'); 13 C NMR (DMSO d_6) δ 166.0, 160.7, 150.1, 145.3, 133.8, 129.7, 129.6, 129.2, 91.5 (d, J = 187.0 Hz), 85.9 (d, J = 15.9 Hz), 75.5, 69.2, 65.6, 33.1 (d, J = 20.1 Hz); Anal. Calcd. for $C_{16}H_{14}FIN_2O_5$: C, 41.76; H, 3.07; N, 6.09. Found: C, 41.64; H, 3.08; N, 6.10. **15**: 172-174 °C; $[\alpha]_D^{25}$ +4.3° (c 0.75, MeOH); UV (EtOAc) λ_{max} 277.5 nm; IR (KBr) 1709, 1680 cm⁻¹; ¹H NMR (DMSO- d_6): δ 11.85 (s, 1H, NH, D₂O exch.); 8.10 (s, 1H, H-6); 8.09 (d, 2H, Ar-H, J = 7.7 Hz); 7.76 (t, 1H, Ar-H, J = 7.4 Hz); 7.62 (t, 2H, Ar-H, J= 7.6 Hz; 6.03 (d, 1H, H-1', J = 17.0 Hz); 5.62 (dd, 1H, H-2', J = 53.1 and 5.5 Hz); 5.08-5.02 (m, 1H, H-4'); 4.49-4.40 (m, 2H, H-5'); 2.83-2.67 and 2.29-2.18 (m, 2H, H-3'); ¹³C NMR $(DMSOd_6) \delta 165.9, 161.1, 150.5, 145.8, 133.8, 129.7, 129.6, 129.1, 96.6 (d, <math>J = 179.0 \text{ Hz}),$ 93.2 (d, J = 37.3 Hz), 80.2, 69.8, 66.6, 33.1 (d, J = 20.9 Hz); Anal. Calcd. for $C_{16}H_{14}FIN_2O_5$: C, 41.78; H, 3.07; N, 6.07. Found: C, 41.43; H, 3.10; N, 6.11.

5-Chloro-1-(5-*O*-benzoyl-2,3-dideoxy-2-fluoro-(β and α)-L-threo-pentofuranosyl)uracil (16 and 17). 5-Chlorouracil (2.00 g, 13.60 mmol), 7 (0.93 g, 4.06 mmol), and TMSOTf (0.25 mL, 1.30 mmol) were reacted for 16 h to give a mixture of 16 and 17, which was separated by flash silica gel column chromatography (40% EtOAc/hexanes) and recrystallized in EtOAc to afford 16 (0.30 g, 20%) and 17 (0.40 g, 26%) as white solids. 16: mp 181-182 °C; $[\alpha]_D^{25}$ -69.1° (c 0.32, EtOAc); UV (EtOAc) λ_{max} 271.5 nm; IR (KBr) 1718, 1678, 1626, 1076 cm⁻¹; ¹H NMR (DMSO- d_6): δ 11.86 (s, 1H, NH, D₂O exch.); 7.82 (d, 2H, Ar-H, J = 8.1 Hz); 7.65 (d, 1H, H-6, J = 1.4 Hz); 7.49 (t, 1H, Ar-H, J = 7.2 Hz); 7.35 (t, 2H, Ar-H, J = 7.7 Hz); 5.87 (dd, 1H, H-1', J = 19.1 and 3.2 Hz); 5.12 (d, 1H, H-2', J = 58.1 Hz); 4.41-4.33 (m, 3H, H-4' and H-5'); 2.60-2.44 and 2.12-2.00 (m, 2H, H-3'); ¹³C NMR (DMSO d_6) δ 166.0, 159.1, 149.5, 138.2, 133.9, 129.7, 129.5, 129.1, 107.2, 91.5 (d, J = 186.1 Hz), 85.9 (d, J =

14.9 Hz), 75.5, 65.7, 33.1 (d, J = 19.4 Hz); Anal. Calcd. for $C_{16}H_{14}ClFN_2O_5$: C, 52.12; H,

3.83; N, 7.60. Found: C, 52.25; H, 3.87; N, 7.57. **17**: mp 170-171 °C; $[\alpha]_D^{25}$ +4.3° (c 0.34, EtOAc); UV (EtOAc) λ_{max} 272.5 nm; IR (KBr) 1709, 1072 cm⁻¹; ¹H NMR (DMSO- d_6): δ 11.94 (s, 1H, NH, D₂O exch.); 8.00 (d, 2H, Ar-H, J = 8.3 Hz); 7.97 (s, 1H, H-6); 7.67 (t, 1H, Ar-H, J = 8.3 Hz); 7.53 (t, 2H, Ar-H, J = 7.6 Hz); 5.95 (d, 1H, H-1', J = 16.2 Hz); 5.50 (dd, 1H, H-2', J = 52.8 and 5.2 Hz); 5.01-4.99 (m, 1H, H-4'); 4.40-4.31 (m, 2H, H-5'); 2.71-2.48 and 2.21-2.11 (m, 2H, H-3'); ¹³C NMR (DMSO d_6) δ 165.3, 159.0, 149.3, 138.0, 133.2, 129.2, 129.0, 128.5, 107.1, 96.0 (d, J = 178.9 Hz), 92.4 (d, J = 37.1 Hz), 79.7, 66.1, 32.2 (d, J = 20.5 Hz); Anal. Calcd. for $C_{16}H_{14}ClFN_2O_5$: C, 52.12; H, 3.83; N, 7.60. Found: C, 52.09; H, 3.85; N, 7.60.

General procedure for condensation of bromide 7 with 5-substituted cytosines and thymine.

Method A: Cytosine (0.33 g, 3.00 mmol) was suspended in dry CH_3CN (20 mL), treated with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA, 6 mL), and stirred at rt for 30 min. Volatiles were distilled from the homogeneous mixture and the resultant solid was dried under vacuum. The residue of the brominated sugar 7 (0.21 g, 0.86 mmol) was taken up into dry DCE (15 mL) and added to the base, then the reaction mixture was refluxed for 16 h under N_2 . After cooling, the solvent was removed and the residue was purified by preparative TLC (10% MeOH/CHCl₃) to provide 18 as a solid (0.13 g, 45%) after coevaporation with hexanes.

1-(5-*O*-Benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine (18). UV (MeOH) λ_{max} 271.5 nm; ¹H NMR (CDCl₃): δ 8.25 (d, 2H, Ar-H, J = 5.9 Hz); 7.75 (d, 1H, H-6, J = 7.4 Hz); 7.61 (t, 1H, Ar-H, J = 7.3 Hz); 7.48 (t, 2H, Ar-H, J = 7.4 Hz); 6.06 (d, 1H, H-1', J = 19.4 Hz); 5.82 (d, 1H, H-5, J = 7.5 Hz); 5.78 (s, 2H, NH₂, D₂O exch.); 5.31 (dm, 1H, H-2', J = 54.0 Hz); 4.59 (m, 3H, H-4' and H-5'); 2.80-2.23 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 166.8, 161.9, 163.8, 145.2, 133.7, 130.1, 129.9, 129.0, 96.8, 90.8 (d, J = 189.1 Hz), 88.0 (d, J = 16.3 Hz), 75.0, 65.5, 34.0 (d, J = 21.0 Hz); *Anal.* Calcd. for C₁₆H₁₆FN₃O₄·O.13CHCl₃: C, 55.56; H, 4.62; N, 12.04. Found: C, 55.90; H, 4.98; N, 11.68.

Method B: A mixture of 5-fluorocytosine (0.90 g, 6.97 mmol), hexamethyldisilazane (20 mL), and a catalytic amount of $(NH_4)_2SO_4$ was refluxed for 2 h under nitrogen. The clear solution obtained was concentrated to dryness *in vacuo*. The residue of the brominated sugar **7** (0.90 g, 3.73 mmol) was taken up into dry DCE (20 mL) and added to the base. The reaction mixture was refluxed for 6 h under nitrogen, washed with sat NaHCO₃ solution (30 mL), dried (Na_2SO_4) , filtered through Celite pad and concentrated *in vacuo*. The crude mixture was purified by flash silica gel column chromatography (3% MeOH/CHCl₃) and recrystallized in hexanes/EtOAc/MeOH (2:1:1) to obtain **19** (0.96 g, 73%) as white crystals.

5-Fluoro-1-(5-*O*-benzoyl-2,3-dideoxy-2-fluoro-β-L-*threo*-pentofuranosyl) cytosine (19). mp 167-168 °C; $[\alpha]_D^{25}$ -35.3° (c 0.70, CH₂Cl₂); UV (CH₂Cl₂) λ_{max} 284.0 nm;

cytosine (19). mp 167-168 °C; $[α]_0^{25}$ -35.3° (c 0.70, CH₂Cl₂); UV (CH₂Cl₂) $λ_{max}$ 284.0 nm; IR (KBr) 3437, 1722, 1680, 1066 cm⁻¹; ¹H NMR (CDCl₃): δ 8.08 (dd, 2H, Ar-H, J = 7.9 and 1.3 Hz); 7.72 (dd, 1H, H-6, J = 6.3 and 1.4 Hz); 7.59 (t, 1H, Ar-H, J = 7.3 Hz);7.46 (t, 3H, Ar-H and NH₂, J = 7.6 Hz, D₂O exch.); 6.07 (dt, 1H, H-1', J = 19.9 and 1.9 Hz); 5.53 (s, 1H, NH₂, D₂O exch.); 5.33 (dm, 1H, H-2', J = 53.5 Hz); 4.63-4.49 (m, 3H, H-4' and H-5'); 2.68-2.29 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 166.7, 158.5 (d, J = 13.7 Hz), 154.1, 136.5 (d, J = 241.3 Hz), 133.7, 130.1, 129.9, 128.9, 126.9 (d, J = 33.1 Hz), 90.5 (d, J = 187.8 Hz), 87.8 (d, J = 16.3 Hz), 75.7, 66.1, 34.0 (d, J = 21.0 Hz); Anal. Calcd. for C₁₆H₁₅F₂N₃O₄: C, 54.73; H, 4.27; N, 11.96. Found: C, 54.74; H, 4.28; N, 12.06.

5-Bromo-1-(5-*O***-benzoyl-2,3-dideoxy-2-fluoro-**β-L-*threo***-pentofuranosyl) cytosine (20)**. **5-Bromocytosine (0.90 g, 4.74 mmol), hexamethyldisilazane (20 mL) and a**

catalytic amount of $(NH_4)_2SO_4$ were refluxed for 2 h under nitrogen. The crude mixture was purified by flash silica gel column chromatography (3% MeOH/CH₂Cl₂) and recrystallized in EtOAc:CH₂Cl₂:hexanes (2:1:1) to obtain (0.72 g, 75%) of **20** as white crystals. mp 124-125 °C; $[\alpha]_D^{25}$ -75.2° (c 0.66, CHCl₃); UV (CHCl₃) λ_{max} 289.0 nm; IR (KBr) 3414, 1716, 1633, 1074 cm⁻¹; ¹H NMR (CDCl₃): δ 8.41 (s, 1H, NH₂, D₂O exch.); 8.09 (d, 2H, Ar-H, J = 8.6 Hz); 7.91 (d, 1H, H-6, J = 1.2 Hz); 7.58 (t, 1H, Ar-H, J = 7.4 Hz); 7.46 (t, 2H, Ar-H, J = 9.5 Hz); 6.09 (dd, 1H, H-1', J = 19.8 and 2.6 Hz); 5.78 (s, 1H, NH₂, D₂O exch.); 5.33 (dm, 1H, H-2', J = 53.5 Hz); 4.62-4.51 (m, 3H, H-4' and H-5'); 2.70-2.30 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 166.8, 162.9, 154.7, 142.7, 133.7, 130.1, 129.9, 128.9, 89.9 (d, J = 188.4 Hz), 88.1, 87.8 (d, J = 23.0 Hz), 75.9, 66.0, 34.0 (d, J = 20.9 Hz) *Anal.* Calcd. for C₁₆H₁₅BrFN₃O₄: C, 46.63; H, 3.64; N, 10.19. Found: C, 46.73; H, 3.65; N, 10.24.

5-Iodo-1-(5-*O***-benzoyl-2,3-dideoxy-2-fluoro-**β-L-*threo***-pentofuranosyl) cytosine** (21). 5-Iodocytosine (1.20 g, 5.06 mmol), hexamethyldisilazane (20 mL), and a catalytic amount of (NH₄)₂SO₄ were refluxed for 2 h under nitrogen. The crude mixture was purified by flash silica gel column chromatography (3% MeOH/EtOAc) and recrystallized in EtOAc to obtain (0.76 g, 58%) of 21 as a white foam. mp 104-106 °C; [α]_D²⁵ -50.5° (c 0.64, CHCl₃); IR (KBr) 3453, 1722, 1651, 1070 cm⁻¹; ¹H NMR (CDCl₃): δ 8.10 (dd, 3H, Ar-H and NH₂, J = 8.7 and 1.4 Hz, D₂O exch.); 7.99 (d, 1H, H-6, J = 1.5 Hz); 7.59 (t, 1H, Ar-H, J = 7.4 Hz); 7.47 (t, 2H, Ar-H, J = 7.5 Hz); 6.08 (dd, 1H, H-1', J = 19.8 and 2.6 Hz); 5.68 (s, 1H, NH₂, D₂O exch.); 5.33 (dm, 1H, H-2', J = 53.5 Hz); 4.62-4.51 (m, 3H, H-4' and H-5'); 2.70-2.31 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 166.8, 164.2, 154.8, 148.3, 133.7, 130.2, 129.9, 129.0, 90.4 (d, J = 189.0 Hz), 88.0 (d, J = 16.9 Hz), 75.9, 65.9, 56.3, 34.0 (d, J = 20.6 Hz); *Anal.* Calcd. for C₁₆H₁₅FIN₃O₄: C, 41.86; H, 3.26; N, 9.15. Found: C, 41.82; H, 3.37; N, 9.08.

5-Methyl-1-(5-*O*-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl) cytosine (22). 5-Methylcytosine (1.00 g, 7.99 mmol), hexamethyldisilazane (20 mL), and a catalytic amount of (NH₄)₂SO₄ were refluxed for 2 h under nitrogen. The crude mixture was purified by preparative TLC (10% MeOH/CH₂Cl₂) and recrystallized in EtOAc to obtain 22 (0.29 g, 40%) as white crystals. mp 98-100 °C; [α]_D²⁵ -99.5° (c 0.31, CHCl₃); UV (CHCl₃) λ_{max} 282.5 nm; IR (KBr) 1718, 1660, 1070 cm⁻¹; ¹H NMR (CDCl₃): δ 8.09 (d, 2H, Ar-H, J = 8.1 Hz); 7.59 (m, 1H, Ar-H); 7.48 (s, 1H, H-6); 7.46 (t, 2H, Ar-H, J = 9.5 Hz); 6.14 (dd, 1H, H-1', J = 20.6 and 2.6 Hz); 5.32 (dm, 1H, H-2', J = 53.6 Hz); 5.25 (s, 2H, NH₂, D₂O exch.); 4.61-4.49 (m, 3H, H-4' and H-5'); 2.67-2.29 (m, 2H, H-3'); 1.90 (s, 3H, CH₃); ¹³C NMR (CDCl₃) δ 166.7, 165.9, 156.1, 140.0, 133.7, 130.1, 130.0, 128.9, 101.3, 91.1 (d, J = 187.0 Hz), 87.7 (d, J = 16.0 Hz), 75.4, 66.2, 34.1 (d, J = 20.6 Hz), 13.5; *Anal.* Calcd. for C₁₇H₁₈FN₃O₄: C, 56.73; H, 5.43; N, 11.67. Found: C, 56.60; H, 5.45; N, 11.67.

5-Chloro-1-(5-*O*-benzoyl-2,3-dideoxy-2-fluoro-β-L-*threo*-pentofuranosyl) cytosine (23). 5-Chlorocytosine (1.00 g, 6.86 mmol), hexamethyldisilazane (20 mL), and a catalytic amount of (NH₄)₂SO₄ were refluxed for 2 h under nitrogen. The crude mixture was purified by flash silica gel column chromatography (1% MeOH/EtOAc) and recrystallized in EtOAc to obtain 23 (0.26 g, 33%) as white crystals. mp 84-86 °C; $[\alpha]_D^{25}$ -97.8° (c 0.45, EtOAc); UV (CHCl₃) λ_{max} 283.0 nm; IR (KBr) 1720, 1645, 1070 cm⁻¹; ¹H NMR (DMSO- d_6): δ 7.99 (dd, 2H, Ar-H, J = 8.4 and 1.3 Hz); 7.97 (s, 1H, NH₂, D₂O exch.); 7.73 (s, 1H, H6); 7.66 (t, 1H, Ar-H, J = 6.2 Hz); 7.54 (d, 2H, Ar-H, J = 8.0 Hz); 7.33 (s, 1H, NH₂, D₂O exch.); 5.99 (dd, 1H, H-1', J = 19.5 and 2.9 Hz); 5.26 (dd, 1H, H-2', J = 54.6 and 3.3 Hz); 4.54-4.49 (m, 3H, H-4' and H-5'); 2.77-2.16 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 166.1, 161.8, 153.4, 139.6, 133.9, 129.7,

129.5, 129.1, 99.0, 91.2 (d, J = 185.3 Hz), 86.8 (d, J = 15.3 Hz), 75.3, 65.9, 33.3 (d, J = 20.7 Hz); *Anal.* Calcd. for $C_{16}H_{15}CIFN_3O_4\cdot0.7H_2O$: C, 50.52; H, 4.35; N, 11.05. Found: C, 50.45; H, 4.34; N, 11.07.

1-(5-*O*-Benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)thymine (24). Thymine (0.65 g, 5.19 mmol) was suspended in dry CH₃CN (34.6 mL), treated with BSTFA (6 mL), and stirred at rt for 30 min under nitrogen. The crude mixture was purified by preparative TLC (5% MeOH/CHCl₃) to yield 24 (0.20 g, 36%) as a white solid. mp 152-153 °C; [α]_D²⁵-104.9° (c 0.07, MeOH); UV (MeOH) λ_{max} 265 nm; IR (KBr) 3190, 1718, 1662, 1070 cm⁻¹; ¹H NMR (DMSO- d_6): δ 11.40 (bs, 1H, NH, D₂O exch.); 8.02 (d, 2H, Ar-H, J = 8.0 Hz); 7.68 (t, 1H, Ar-H, J = 8.0 Hz); 7.55 (t, 2H, Ar-H, J = 8.0 Hz); 7.39 (s, 1H, H-6); 6.06 (dd. 1H. H-1', J = 20.0 and 4.0 Hz); 5.29 (d, 1H, H-2', J = 64.0 Hz); 4.57-4.48 (m, 3H, H-4' and H-5'); 2.79-2.19 (m, 2H, H-3'); 1.63 (s, 3H, CH₃); 13 C NMR (CDCl₃) δ 163.7, 161.5, 148.1. 134.5. 131.6, 127.4, 127.2, 126.8, 106.4, 89.3 (d, J = 186.5 Hz), 83.0 (d, J = 15.4 Hz), 72.6, 63.5. 31.0 (d, J = 19.9 Hz), 9.99; *Anal.* Calcd. for C₁₇H₁₇FN₂O₅: C, 58.65; H, 4.88; N, 8.04. Found: C, 58.34; H, 4.95; N, 7.99.

General procedure for debenzoylation.

A solution of **8** (0.15 g, 0.45 mmol) was stirred in sat methanolic ammonia in a steel bomb at rt for 48 h, the solvent was removed under vacuum and the residue was purified by preparative TLC (10% MeOH/CHCl₃) to yield white crystals **25** (0.09 g, 89%), which was recrystallized from a mixture of ethyl acetate and hexanes (2:1).

1-(2,3-Dideoxy-2-fluoro-β-L-threo-pentofuranosyl)uracil (25). mp 140-141 °C: $[\alpha]_{D}^{25}$ -110.7° (c 0.09, MeOH); UV (H,O) λ_{max} 260.5 nm (£ 7570) (pH 2); 260.5 nm (£ 9980) (pH 7); 260.5 nm (ε 5800) (pH 11); IR (KBr) 3439, 3190, 1713, 1686, 1051, 1039 cm⁻¹; MS (ESI) m/e 230.8 (MH)⁺; ¹H NMR (DMSO- d_s): δ 11.42 (s, 1H, NH, D₂O exch.); 7.75 (d. 1H. H-5, J = 8.1 Hz); 5.96 (dd, 1H, H-1', J = 16.8 and 3.6 Hz); 5.62 (dd, 1H, H-6, J = 8.1 and 1.86 Hz); 5.28 (dm, 1H, H-2', J = 54.9 Hz); 5.02 (bs, 1H, OH); 4.12-4.06 (m, 1H, H-4'); 3.59-3.48 (m, 2H, H-5'); 2.53-1.98 (m, 2H, H-3'); 13 C NMR (D₂O) δ 143.0, 135.6, 127.8, 101.6, 91.6 (d, J = 186.0 Hz), 86.2 (d, J = 16.0 Hz), 78.5, 63.6, 32.7 (d, J = 20.3 Hz); Anal. Calcd. forC₉H₁₁FN₂O₄: C, 46.98; H, 4.78; N, 12.17. Found: C, 47.02; H, 4.83; N, 12.11. 1-(2,3-Dideoxy-2-fluoro-α-L-threo-pentofuranosyl)uracil (26), 9 (0.22 g, 0.66 mmol) was debenzoylated and the residue was purified by preparative TLC (10% MeOH/CHCl₃) to yield 26 (0.09 g, 89%) as a hygroscopic amorphous powder, which was triturated with diethyl ether. $[\alpha]_0^{25}$ +40.1° (c 0.11, MeOH); UV (H₂O) λ_{max} 260.5 nm (ϵ 8200) (pH 2); 261.5 nm (ϵ 10300) (pH 7); 260.5 nm (£ 7750) (pH 11); IR (KBr) 3258, 2966, 1705, 1664, 1059 cm⁻¹: MS (ESI) m/e 230.8 MH⁺; ¹H NMR (DMSO- d_s): δ 11.38 (s, 1H, NH, D₂O exch.); 7.53 (d, 1H, H-5, J = 7.76 Hz; 5.88 (d, 1H, H-1', J = 15.32 Hz); 5.58 (d, 1H, H-6, J = 7.75 Hz); 5.40 (d. 1H, H-6) 2', J = 52.7 Hz); 4.94 (s, 1H, OH, D₂O exch.); 4.53 (s, 1H, H-4'); 3.59-3.38 (m, 2H, H-5'); 2.44-1.99 (m, 2H, H-3'); 13 C NMR (DMSO- d_6) δ 163.7, 150.6, 141.2, 101.8, 96.6 (d, J =177.7 Hz), 91.83 (d, J = 35.9 Hz), 82.9, 63.9, 32.4 (d, J = 19.9 Hz); Anal. Calcd. for C₉H₁₁FN₂O₄: C, 46.90; H, 4.70; N, 12.11. Found: C, 47.08; H, 4.77; N, 12.05. 5-Fluoro-1-(2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)uracil (27). 10 (0.04 g, 0.11 mmol) was debenzoylated and the residue was purified by flash silica gel column chromatography (10% MeOH/CHCl₃) to yield 27 (0.03 g, 90%) which was recrystallized from methanol. mp 156-157 °C; $[\alpha]_D^{25}$ -147.3° (c 0.14, MeOH); UV (H₂O) λ_{max} 266.5 nm (ϵ 9460)

(pH 2); 267.0 nm (ε 8950) (pH 7); 266.5 nm (ε 7060) (pH 11); IR (KBr) 1709 cm⁻¹; MS (FAB)

m/e 249 (MH)⁺; ¹H NMR (CDCl₃): δ 11.79 (s, 1H, NH, D₂O exch.); 7.95 (dd, 1H, H-6, J = 7.1 and 1.0 Hz); 5.77 (dm, 1H, H-1', J = 15.1 Hz); 5.13 (dm, 1H, H-2', J = 54.8 Hz); 4.95 (t, 1H, OH, D₂O exch.); 3.94-3.89 (m, 1H, H-4'); 3.46-3.29 (m, 2H, H-5'); 2.33-2.19 and 1.95-1.82 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 157.3 (d, J = 26.2 Hz), 149.0, 139.7 (d, J = 229.3 Hz), 126.0 (d, J = 34.6 Hz), 91.6 (d, J = 186.8 Hz), 85.0 (d, J = 16.1 Hz), 78.3, 62.4, 32.1 (d, J = 19.9 Hz); Anal. Calcd. for C₉H₁₀F₂N₂O₄: C, 43.56; H, 4.06; N, 11.29. Found: C, 43.47; H, 4.06; N, 11.19.

- 5-Fluoro-1-(2,3-dideoxy-2-fluoro-α-L-threo-pentofuranosyl)uracil (28). 11 (0.09 g, 0.25 mmol) was debenzoylated and the residue was purified by flash silica gel column chromatography (10% MeOH/CHCl₃) to yield 28 (0.06 g, 96%) as a hygroscopic amorphous powder, which was triturated with EtOAc. [α]_D²⁵ +2.4° (c 0.54, MeOH); UV (H₂O) λ_{max} 268.0 nm (ε 7700) (pH 2); 267.0 nm (ε 5200) (pH 7); 268.0 nm (ε 8300) (pH 11); IR (KBr) 1716 cm⁻¹; MS (FAB) *m/e* 249 (MH)⁺; ¹H NMR (CDCl₃): δ 11.92 (s, 1H, NH, D₂O exch.); 7.88 (d, 1H, H-6, J = 6.9 Hz); 5.88 (d, 1H, H-1', J = 15.0 Hz); 5.41 (dd, 1H, H-2', J = 52.7 and 5.1 Hz); 4.97 (t, 1H, OH, D₂O exch.); 4.63-4.60 (m, 1H, H-4'); 3.50-3.33 (m, 2H, H-5'); 2.48-2.32 and 2.12-2.01 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 157.6 (d, J = 26.3 Hz), 149.2, 140.4 (d, J = 229.7 Hz), 125.4 (d, J = 34.7 Hz), 96.5 (d, J = 179.0 Hz), 91.6 (d, J = 35.7 Hz), 82.9, 63.9, 32.1 (d, J = 19.8 Hz); *Anal.* Calcd. for C₉H₁₀F₂N₂O₄·0.4EtOAc: C, 44.92; H, 4.69; N, 9.88. Found: C, 45.07; H, 4.74; N, 9.99.
- 5-Bromo-1-(2,3-dideoxy-2-fluoro-β-L-*threo*-pentofuranosyl)uracil (29). 12 (0.10 g, 0.24 mmol) was debenzoylated and the residue was purified by flash silica gel column chromatography (10% MeOH/CHCl₃) to yield 29 (0.07 g, 91%) which was recrystallized from methanol/EtOAc (2:1). mp 154-156 °C; $[\alpha]_D^{25}$ -93.9° (c 0.24, MeOH); UV (H₂O) λ_{max} 278.0 nm (ε 8770) (pH 2); 278.0 nm (ε 8120) (pH 7); 275.0 nm (ε 5840) (pH 11); IR (KBr) 1714, 1674 cm⁻¹; MS (FAB) *m/e* 309 (MH)⁺; ¹H NMR (CDCl₃): δ 12.04 (s, 1H, NH, D₂O exch.); 8.32 (s, 1H, H-6); 6.03 (dd, 1H, H-1', J = 15.0 and 3.8 Hz); 5.39 (dm, 1H, H-2', J = 54.9 Hz); 5.25 (t, 1H, OH, D₂O exch.); 4.19-4.15 (m, 1H, H-4'); 3.73-3.53 (m, 2H, H-5'); 2.56-2.45 and 2.21-2.05 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 159.4, 149.8, 140.9, 127.8, 91.6 (d, J = 186.0 Hz), 85.2 (d, J = 16.0 Hz), 78.4, 62.2, 32.0 (d, J = 20.2 Hz); *Anal.* Calcd. for C₉H₁₀BrFN₂O₄·0.1 EtOAc: C, 35.52; H, 3.42; N, 8.81. Found: C, 35.48; H, 3.32; N, 9.06.
- **5-Bromo-1-(2,3-dideoxy-2-fluoro-α-L-***threo***-pentofuranosyl)uracil** (**30**). **13** (0.12 g, 0.29 mmol) was debenzoylated and the residue was purified by flash silica gel column chromatography (5% MeOH/CHCl₃) to yield **30** (0.08 g, 86%) as a white solid. mp 148-149 °C; $[\alpha]_D^{25}$ -12.2° (c 0.24, MeOH); UV (H₂O) λ_{max} 279.0 nm (ε 9220) (pH 2); 278.5 nm (ε 8620) (pH 7); 275.0 nm (ε 7000) (pH 11); IR (KBr) 1697 cm⁻¹; MS (FAB) *m/e* 309 (MH)⁺; ¹H NMR (CDCl₃): δ 11.90 (s, 1H, NH, D₂O exch.); 7.96 (s, 1H, H-6); 5.87 (d, 1H, H-1', J = 15.7 Hz); 5.46 (dd, 1H, H-2', J = 53.1 Hz); 4.95 (t, 1H, OH, D₂O exch.); 4.62-4.56 (m, 1H, H-4'); 3.50-3.38 (m, 2H, H-5'); 2.51-2.37 and 2.09-1.98 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 159.7, 150.1, 140.7, 132.9, 96.8 (d, J = 137.2 Hz), 92.4 (d, J = 36.8 Hz), 83.2, 63.8, 32.4 (d, J = 20.3 Hz); *Anal.* Calcd. for C₉H₁₀BrFN₂O₄: C, 34.97; H, 3.26; N, 9.06. Found: C, 35.08; H, 3.28; N, 8.99.
- 5-Iodo-1-(2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)uracil (31). 14 (0.17 g, 0.36 mmol) was debenzoylated and the residue was purified by flash silica gel column chromatography (5% MeOH/CHCl₃) to yield 31 (0.09 g, 69%) as a white solid, which was recrystallized from methanol. mp 176-178 °C; $[\alpha]_D^{25}$ -67.0° (c 0.31, MeOH); UV (H,O) λ_{max}

285.0 nm (ϵ 6100) (pH 2); 286.5 nm (ϵ 5950) (pH 7); 276.5 nm (ϵ 5310) (pH 11); IR (KBr) 1714 cm⁻¹; MS (ESI) *m/e* 357 (MH)⁺; ¹H NMR (CDCl₃): δ 11.83 (s, 1H, NH, D₂O exch.); 8.25 (s, 1H, H-6); 5.97 (dd, 1H, H-1', J = 15.2 and 3.9 Hz); 5.33 (dm, 1H, H-2', J = 54.9 Hz); 5.18 (t, 1H, OH, J = 5.6 Hz, D₂O exch.); 4.15-4.10 (m, 1H, H-4'); 3.67-3.48 (m, 2H, H-5'); 2.53-2.39 and 2.15-2.02 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 160.7, 150.2, 145.6, 91.6 (d, J = 187.2 Hz), 85.1 (d, J = 15.7 Hz), 78.3, 68.9, 62.2, 32.1 (d, J = 19.8 Hz); *Anal.* Calcd. for C₉H₁₀FIN₂O₄: C, 30.36; H, 2.83; N, 7.87. Found: C, 30.46; H, 2.90; N, 7.72.

- **5-Iodo-1-(2,3-dideoxy-2-fluoro-α-L-***threo***-pentofuranosyl)uracil** (32). **15** (0.16 g, 0.34 mmol) was debenzoylated and the residue was purified by flash silica gel column chromatography (5% MeOH/CHCl₃) to yield **32** (0.10 g, 82%) as a white solid. mp 156-158 °C; $[\alpha]_D^{25}$ -23.8° (c 0.31, MeOH); UV (H₂O) λ_{max} 287.0 nm (ε 7100) (pH 2); 286.5 nm (ε 6680) (pH 7); 278.5 nm (ε 5370) (pH 11); IR (KBr) 1714, 1664, 1068 cm⁻¹; MS (ESI) *m/e* 357 (MH)⁺; ¹H NMR (CDCl₃): δ 11.74 (s, 1H, NH, D₂O exch.); 7.92 (s, 1H, H-6); 5.85 (d, 1H, H-1', J = 16.1 Hz); 5.44 (dd, 1H, H-2', J = 53.2 and 4.6 Hz); 4.92 (s, 1H, OH, D₂O exch.); 4.56-4.51 (m, 1H, H-4'); 3.44-3.42 (m, 2H, H-5'); 2.51-2.36 and 2.07-1.95 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 161.1, 150.5, 145.4, 96.6 (d, J = 178.7 Hz), 92.5 (d, J = 36.7 Hz), 83.2, 69.7, 63.8, 32.6 (d, J = 20.1 Hz); *Anal.* Calcd. for C₉H₁₀FIN₂O₄: C, 30.36; H, 2.83; N, 7.87. Found: C, 30.85; H, 2.81; N, 7.74.
- **5-Chloro-1-(2,3-dideoxy-2-fluoro-**β-L-*threo*-pentofuranosyl)uracil (33). **16** (0.13 g, 0.35 mmol) was debenzoylated and the residue was purified by flash silica gel column chromatography (10% MeOH/CHCl₃) to yield **33** (0.09 g, 97%) as white crystals, which was recrystallized from methanol. mp 160-162 °C; [α]_D²⁵-101.7° (c 0.20, MeOH); UV (H₂O) λ _{max} 275.5 nm (ε 9350) (pH 2); 274.5 nm (ε 8540) (pH 7); 273.0 nm (ε 6110) (pH 11); IR (KBr) 1714, 1682 cm⁻¹; MS (FAB) *m/e* 265 (MH)⁺; ¹H NMR (CDCl₃): δ 12.02 (s, 1H, NH, D₂O exch.); 8.20 (s, 1H, H-6); 5.98 (dd, 1H, H-1', J = 15.0 Hz); 5.34 (dm, 1H, H-2', J = 54.9 Hz); 5.19 (t, 1H, OH, D₂O exch.); 4.13-4.12 (m, 1H, H-4'); 3.67-3.49 (m, 2H, H-5'); 2.54-2.40 and 2.16-2.03 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 159.2, 149.6, 138.6, 107.0, 91.6 (d, J = 187.2 Hz), 85.2 (d, J = 15.7 Hz), 78.4, 62.3, 32.0 (d, J = 20.2 Hz); *Anal.* Calcd. for C₉H₁₀CIFN₂O₄: C, 40.85; H, 3.81; N, 10.59. Found: C, 40.95; H, 3.80; N, 10.52.
- **5-Chloro-1-(2,3-dideoxy-2-fluoro-**α-L-*threo*-pentofuranosyl)uracil (34). 17 (0.10 g, 0.27 mmol) was debenzoylated and the residue was purified by flash silica gel column chromatography (10% MeOH/CHCl₃) to yield 34 (0.05 g, 66%) as a white solid. mp 60-62 °C; $[α]_D^{25}$ -0.8° (c 0.21, MeOH); UV (H₂O) $λ_{max}$ 277.0 nm (ε 8670) (pH 2); 276.0 nm (ε 9200) (pH 7); 273.5 nm (ε 6110) (pH 11); IR (KBr) 1707 cm⁻¹; MS (FAB) *m/e* 265 (MH)⁺; ¹H NMR (CDCl₃): δ 11.95 (s, 1H, NH, D₂O exch.); 7.90 (s, 1H, H-6); 5.88 (d, 1H, H-1', J = 15.4 Hz): 5.45 (dd, 1H, H-2', J = 52.7 and 5.0 Hz); 4.96 (s, 1H, OH, D₂O exch.); 4.63-4.60 (m, 1H, H-4'); 3.49-3.40 (m, 2H, H-5'); 2.51-2.36 and 2.10-2.00 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 159.6, 149.8, 138.3, 107.6, 96.6 (d, J = 178.4 Hz), 92.3 (d, J = 35.6 Hz), 83.2, 63.8, 32.3 (d, J = 19.3 Hz); *Anal.* Calcd. for C₉H₁₀CIFN₂O₄: C, 40.85; H, 3.81; N, 10.59. Found: C, 40.75; H, 3.81; N, 10.64.
- 1-(2,3-Dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine (35). 18 (0.09 g. 0.27 mmol) was debenzoylated and the residue was purified by silica gel column chromatography (15% MeOH/CHCl₃) to provide 35 as white crystals (0.05 g, 90%), which was recrystallized from a mixture of MeOH and ether (1:1). mp 142-144 °C; $[\alpha]_D^{25}$ -210.7° (c 0.12, MeOH); UV (H₂O) λ_{max} 272.0 nm (ε 8140) (pH 2), 271.5 nm (ε 8680) (pH7), 271.5 nm (ε 9860) (pH 11); ¹H NMR

(DMSO- d_6): δ 7.67 (d, 1H, H-6, J = 7.6 Hz); 7.32 (bs, 2H, NH₂, D₂O exch.); 5.94 (dd, 1H, H-1', J = 18.5 and 2.6 Hz); 5.72 (d, 2H, H-5', J = 7.6 Hz); 5.21 (dm, 1H, H-2', J = 58.0 Hz); 4.95 (t, 1H, 5'-OH, J = 3.0 Hz, D₂O exch.); 4.09 (m, 1H, H-4'); 3.51 (m, 1H, H-5); 1.99-2.60 (m, 2H, H-3'); ¹³C NMR (DMSO- d_6) δ 165.5, 154.9, 139.8, 94.8, 92.1 (d, J = 185.8 Hz), 85.8 (d, J = 16.1 Hz), 77.3, 63.5, 33.5 (d, J = 19.0 Hz); Anal. Calcd. for C₉H₁₂FN₃O₃: C, 47.18; H, 5.24; N, 18.34. Found: C, 46.89; H, 5.27; N, 18.07.

- 5-Fluoro-1-(2,3-dideoxy-2-fluoro-β-L-*threo*-pentofuranosyl) cytosine (36). 19 (0.23 g, 0.71 mmol) was debenzoylated and the residue purified by silica gel column chromatography (5% MeOH/CHCl₃) to obtain 36 (0.17 g, 96%) as colorless crystals. mp 192-194 °C; $[\alpha]_D^{25}$ -166.5° (c 1.00, MeOH); UV (H₂O) λ_{max} 285.5 nm (ε 9050) (pH 2); 280.0 nm (ε 7490) (pH 7); 279.5 nm (ε 7730) (pH 11); IR (KBr) 3364, 1686, 1060 cm⁻¹; HRMS (FAB): calculated *m/e* 248.0846. Found: 248.0846 (MH)⁺; ¹H NMR (DMSO- d_6): δ 7.94 (d, 1H, H-6, J = 7.1 Hz); 7.82 (s, 1H, NH₂, D₂O exch.); 7.58 (s, 1H, D₂O exch.); 5.88 (dm, 1H, H-1', J = 17.2 Hz); 5.20 (dm, 1H, H-2', J = 54.8 Hz); 5.04 (t, 1H, 5'-OH, J = 5.8 Hz, D₂O exch.); 4.12-4.06 (m, 1H, H-4'); 3.59-3.46 (m, 2H, H-5'); 2.51-2.36 and 2.10-1.97 (m, 2H, H-3'); ¹³C NMR (DMSO- d_6) δ 157.9 (d, J = 13.3 Hz), 153.3, 136.0 (d, J = 240.0 Hz), 126.6 (d, J = 32.2 Hz), 91.4 (d, J = 185.8 Hz), 86.1 (d, J = 16.1 Hz), 78.1, 62.9, 32.6 (d, J = 20.2 Hz); *Anal*. Calcd. for C₉H₁₁F₂N₃O₃·0.4MeOH: C, 43.44; H, 4.84; N, 16.16. Found: C, 43.55; H, 4.88; N, 16.12.
- 5-Bromo-1-(2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine (37). 20 (0.17 g, 0.42 mmol) was debenzoylated and the residue purified by flash silica gel column chromatography (7% MeOH/CHCl₃) to obtain 37 (0.11 g, 88%). mp 198-200 °C; $[\alpha]_D^{25}$ -115.7° (c 0.32, MeOH); UV (H₂O) λ_{max} 294.5 nm (ε 8350) (pH 2); 286.5 nm (ε 6590) (pH 7); 286.5 nm (ε 6360) (pH 11); IR (KBr) 1658, 1631, 1078 cm⁻¹; MS (FAB) *m/e* 308 (MH)⁺; ¹H NMR (CDCl₃): δ 8.12 (s, 1H, H-6); 8.01 (s, 1H, NH₂, D₂O exch.); 7.16 (s, 1H, NH₂, D₂O exch.); 5.99 (dd, 1H, H-1', J = 17.0 and 3.5 Hz); 5.33 (dm, 1H, H-2', J = 54.8 Hz); 5.17 (t, 1H, OH, J = 5.8 Hz, D₂O exch.); 4.21-4.15 (m, 1H, H-4'); 3.69-3.52 (m, 2H, H-5'); 2.59-2.05 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 162.3, 163.7, 142.6, 132.9, 91.3 (d, J = 191.1 Hz), 86.2 (d, J = 14.0 Hz), 76.1, 62.7, 32.5 (d, J = 20.0 Hz); *Anal.* Calcd. for C₉H₁₁BrFN₃O₃: C, 35.00; H, 3.50; N, 13.60. Found: C, 35.14; H, 3.59; N, 13.38.
- 5-Iodo-1-(2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine (38). 21 (0.09 g, 0.20 mmol) was debenzoylated and the residue purified by preparative TLC (7% MeOH/CHCl₃) to obtain 38 (0.06 g, 84%). mp 220-222 °C; $[\alpha]_D^{25}$ -99.0° (c 0.41, MeOH); UV (H₂O) λ_{max} 305.5 nm (ε 7790) (pH 2); 292.0 nm (ε 5910) (pH 7); 292.0 nm (ε 5690) (pH 11); IR (KBr) 1651, 1072 cm⁻¹; MS (FAB) *m/e* 356 (MH)⁺; ¹H NMR (CDCl₃): δ 8.05 (s, 1H, H-6); 7.89 (s, 1H, NH₂, D₂O exch.); 6.69 (s, 1H, NH₂, D₂O exch.); 5.90 (dd, 1H, H-1', J = 17.2 and 3.5 Hz); 5.24 (dm, 1H, H-2', J = 54.9 Hz); 5.08 (t, 1H, OH, D₂O exch.); 4.12-4.06 (m, 1H, H-4'); 3.60-3.44 (m, 2H, H-5'); 2.51-2.36 and 2.09-1.96 (m, 2H, H-3'); 13 C NMR (CDCl₃) δ 163.4, 153.1, 147.1, 90.5 (d, J = 186.1 Hz), 85.2 (d, J = 16.1 Hz), 77.2, 61.9, 55.6, 31.7 (d, J = 20.2 Hz); Anal. Calcd. for C₉H₁₁FIN₃O₃: C, 30.45; H, 3.09; N, 11.83. Found: C, 30.58; H, 3.05; N, 11.78.
- 5-Methyl-1-(2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine (39). 22 (0.08 g, 0.23 mmol) was debenzoylated and the residue purified by flash silica gel column chromatography (10% MeOH/CHCl₃) to obtain 39 (0.05 g, 87%). mp 192-194 °C; $[\alpha]_D^{25}$ 146.0° (c 0.32, MeOH); UV (H₂O) λ_{max} 285.5 nm (ε 11100) (pH 2); 276.5 nm (ε 7230) (pH 7); 276.0 nm (ε 7510) (pH 11); IR (KBr) 1670 cm⁻¹; MS (FAB) *m/e* 244 (MH)⁺; ¹H NMR (CDCl₃): δ

7.51 (s, 1H, H-6); 7.34 (s, 1H, NH₂, D₂O exch.); 6.85 (s, 1H, NH₂, D₂O exch.); 5.94 (dd, 1H. H-1', J = 18.6 and 3.3 Hz); 5.22 (dt, 1H, H-2', J = 55.0 and 2.4 Hz); 4.98 (t, 1H, OH, J = 5.8Hz, D₂O exch.); 4.12-4.06 (m, 1H, H-4'); 3.59-3.50 (m, 2H, H-5'); 2.54-2.43 and 2.03-2.01 (m, 2H, H-3'); 1.86 (s, 3H, CH₂); 13 C NMR (CDCl₂) δ 165.8, 155.1, 139.3, 100.6, 91.4 (d, J =185.8 Hz), 85.9 (d, J = 16.2 Hz), 77.6, 63.2, 33.1 (d, J = 20.0 Hz), 13.6; Anal. Calcd. for C₁₀H₁₄FN₃O₃: C, 49.38; H, 5.80; N, 17.28. Found: C, 49.38; H, 5.77; N, 17.14. 5-Chloro-1-(2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine (40). 23 (0.11 g, 0.31 mmol) was debenzoylated and the residue purified by flash silica gel column chromatography (10% MeOH/CHCl₃) to obtain **40** (0.07 g, 90%). mp 180-181 °C; $[\alpha]_0^{25}$ -153.0° (c 0.28, MeOH); UV (H₂O) λ_{max} 292.0 nm (ϵ 10800) (pH 2); 284.5 nm (ϵ 7840) (pH 7); 284.5 nm (ϵ 7680) (pH 11); IR (KBr) 1666, 1082 cm⁻¹; MS (FAB) m/e 264 (MH)⁺; ¹H NMR $(CDCl_1)$: δ 8.02 (s, 1H, H-6); 7.94 (s, 1H, NH₂, D₂O exch.); 7.32 (s, 1H, NH₂, D₂O exch.); = 52.0 and 4.0 Hz); 5.00-4.99 (m, 1H, H-4'); 4.54-4.53 (m, 2H, H-5'); 3.05-2.36 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 165.9, 152.1, 151.4, 149.6, 146.0, 133.8, 131.8, 129.7, 129.6, 129.1. 96.4 (d, J = 179.8 Hz), 90.2 (d, J = 35.4 Hz), 79.8, 66.4, 33.2 (d, J = 20.1 Hz); Anal. Calcd. for C₁₇H₁₄ClFN₄O₃: C, 54.21; H, 3.71; N, 14.87. Found: C, 54.37; H, 3.73; N, 14.64. 2-Isobutyrylamino-6-chloro-9-(5-0-benzoyl-2,3-dideoxy-2-fluoro-(β and α)-Lthreo-pentofuranosyl)purine (44 and 45). A mixture of 2-isobutyrylamino-6-chloropurine (1.50 g, 6.26 mmol), hexamethyldisilazane (50 mL) and (NH₄)₃SO₄ (catalytic amount) was refluxed for 2 h under nitrogen. The clear solution obtained was evaporated to dryness in vacuo. The residue of the brominated sugar 7 (prepared from bromination of 6 (0.90 g, 3.93 mmol)) was taken up into DCE (25 mL) and added to the base, after that TMSOTf (1.2 mL, 6.26 mmol) was added and the reaction mixture was refluxed for 20 h under nitrogen. The reaction was worked up and purified as described for compounds 42 and 43 to obtain 44 (0.21 g, 12%) as white crystals and 45 (0.42 g, 24%) as white crystals, after recrystallized in a mixture of EtOAc and hexanes (1:2). **44**: mp 168-170 °C; $[\alpha]_D^{25}$ +42.9° (c 0.54, CHCl₃); UV (EtOAc) λ_{max} 252.0 nm; IR (KBr) 3190, 1724, 1026 cm⁻¹; ¹H NMR (CDCl₃): δ 8.25 (s, 1H, H-8); 8.15 (s, 1H, NH, D₂O exch.); 8.09 (d, 2H, Ar-H, J = 7.5 Hz); 7.62 (t, 1H, Ar-H, J = 7.5 Hz); 7.51 (t, 2H, Ar-H, J = 7.8 Hz); 6.51 (dd, 1H, H-1', J = 19.5 and 2.1 Hz); 5.50 (d, 1H, H-2', J = 53.1 Hz); 5.09-5.06 (m. 1H. H-4'); 4.54-4.44 (m, 2H, H-5'); 2.81-2.70 (m, 2H, H-3' and CH); 2.46-2.32(m, 1H, H-3'); 1.31 (s, 3H, CH₃); 1.29 (s, 3H, CH₂); ¹³C NMR (CDCl₃) δ 171.7, 164.6, 152.1, 152.6, 140.3, 132.5, 131.6, 131.1, 128.4, 128.2, 127.8, 90.1 (d, J = 184.0 Hz), 73.8, 82.8 (d, J = 23.7 Hz), 65.1, 33.3, 32.1 (d, J = 20.7 Hz), 17.9, 17.0; Anal. Calcd. for $C_{21}H_{21}CIFN_5O_4$: C, 54.63; H, 4.54; N, 15.16. Found: C, 54.33; H, 4.53; N, 14.96. **45**: mp 142-143 °C; $[\alpha]_D^{-25}$ +52.1° (c 1.00, EtOAc); UV (EtOAc) λ_{max} 257.5 nm; IR (KBr) 3285, 1714, 1075; ¹H NMR (CDCl₃): δ 8.06 (s, 1H, H-8); 8.02-8.00 (m, 3H, NH and Ar-H); 7.50 (t, 1H, Ar-H, J = 7.4 Hz); 7.37 (t, 2H, Ar-H, J = 7.6 Hz); 6.20 (d, 1H, H-1', J = 16.64 Hz); 5.86 (dd, 1H, H-2', J = 52.6 and 5.3 Hz); 5.05-4.99 (m, 1H, H-4'); 4.49-4.41 (m, 2H, H-5'); 2.67-2.60 and 2.42-2.36 (m, 1H, H-3'); 1.23 (d, 3H, CH_3 , J = 2.0 Hz); 1.21 (d, 3H, CH_3 , J = 1.6 Hz); 2.67-2.60 (m, 2H, H-3' and CH); ¹³C NMR (CDCl₃) & 175.2, 165.9, 152.1, 149.6, 145.6, 133.8, 129.8, 129.6, 129.4, 129.1, 128.0, 97.1 (d, J = 175.1 Hz), 90.3 (d, J = 22.4 Hz) 80.5, 66.5, 35.1, 33.9 (d, J = 24.0 Hz) Hz), 19.6, 19.5; Anal. Calcd. for $C_{21}H_{21}CIFN_5O_4$: C, 54.63; H, 4.54; N, 15.16. Found: C, 54.35; H, 4.60; N, 14.99.

9-(2,3-Dideoxy-2-fluoro-β-L-*threo***-pentofuranosyl)hypoxanthine** (46). A mixture of 42 (0.59 g, 1.42 mmol), 2-mercaptoethanol (0.4 mL, 5.70 mmol), and NaOMe (0.31 g, 5.74

mmol) in MeOH (75 mL) was refluxed for 5 h. The reaction mixture was cooled, neutralized with glacial HOAc and evaporated to dryness under vacuum. The residue was purified by silica gel column chromatography (CHCl₃/MeOH) (9:1 and 17:3) to obtain **46** (0.30 g, 83%) as white foam. mp 138-140 °C; $[\alpha]_D^{25}$ -54.1° (c 0.35, H₂O); UV (H₂O) λ_{max} 247.5 nm (ϵ 9120) (pH 2); 247.0 nm (ϵ 9380) (pH 7); 252.0 nm (ϵ 9800) (pH 11); IR (KBr) 3389, 1701, 1086; MS (FAB) *m/e* 255 5.92 (dd, 1H, H-1', J = 17.0 and 3.3 Hz); 5.28 (d, 1H, H-2', J = 54.8 Hz); 5.10 (t, 1H, OH, J = 5.9 Hz, D₂O exch.); 4.13-4.12 (m, 1H, H-4'); 3.63-3.47 (m, 2H, H-5'); 2.54-2.39 and 2.12-1.99 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 161.8, 153.6, 140.0, 98.9, 91.4 (d, J = 185.9 Hz), 86.2 (d, J = 16.4 Hz), 78.1, 62.7, 32.5 (d, J = 19.9 Hz); *Anal*. Calcd. for C₉H₁₁ClFN₃O₃: C, 41.00; H, 4.20; N, 15.94. Found: C, 40.94; H, 4.18; N, 15.88.

1-(2,3-Dideoxy-2-fluoro-β-L-threo-pentofuranosyl)thymine (41). 24 (0.07 g, 0.22 mmol) was debenzoylated and the residue was purified by preparative TLC (5% MeOH/CHCl₃) to yield 41 (0.03 g, 68%) as white crystals, which was recrystallized from a mixture of diethyl ether and methanol (1:1). mp 140-142 °C; $[\alpha]_D^{25}$ -145.3° (c 0.09, MeOH); UV (H₂O) λ_{max} 266.0 nm (ε 9340) (pH 2); 266.5 nm (ε 9400) (pH 7); 266.0 nm (ε 7120) (pH 11); IR (KBr) 2843, 1690, 1660, 1059 cm⁻¹; MS (ESI) *m/e* 244.9 (MH)⁺; ¹H NMR (DMSO- d_6): δ 11.36 (bs, 1H, NH, D₂O exch.); 7.61 (s, 1H, H-6); 5.96 (dd, 1H, H-1', J = 16.6 and 3.76 Hz); 5.36-5.20 (dm, 1H, H-2', J = 55.1 Hz); 5.08-5.05 (m, 1H, H-4'); 5.01 (s, 1H, OH, D₂O exch.); 3.62-3.52 (m, 2H, H-5'); 2.49-2.01 (m, 2H, H-3'); 1.76 (s, 3H, CH₃); ¹³C NMR (DMSO- d_6) δ 161.6, 148.1, 130.5, 106.1, 89.2 (d, J = 186.6 Hz), 82.3 (d, J = 16.3 Hz), 75.4, 60.2, 30.1 (d, J = 20.4 Hz), 10.1; *Anal.* Calcd. for C₁₀H₁₃FN₂O₄: C, 49.21; H, 5.32; N, 11.47. Found: C, 49.04; H, 5.44; N, 11.31.

6-Chloro-9-(5-O-benzoyl-2,3-dideoxy-2-fluoro-(β and α)-L-threopentofuranosyl)purine (42 and 43). A mixture of 6-chloropurine (3.00 g, 19.40 mmol), hexamethyldisilazane (50 mL) and (NH₄),SO₄ (catalytic amount) was refluxed for 2 h under argon. The clear solution obtained was concentrated to dryness under vacuum. The residue of the brominated sugar 7 (prepared from the bromination of 6 (1.05 g, 4.38 mmol)) was taken up into dry DCE (50 mL) and added to the base. TMSOTf (3.8 mL, 19.40 mmol) was added then the reaction mixture was refluxed for 24 h under argon. The solution was then washed with sat NaHCO₃ solution (100 mL), dried (Na₂SO₄), filtered through a Celite pad, and concentrated in vacuo to give a yellowish residue, which was purified by flash silica gel column chromatography (EtOAc:hexanes) (1:1) to obtain 42 (0.33 g, 18%) and 43 (0.32 g, 17%) as white crystals, which were recrystallized from a mixture of EtOAc and hexanes (3:1). 42: mp 125-127 °C; $[\alpha]_0^{25}$ -28.4° (c 0.60, CHCl₂); UV (MeOH) λ_{max} 263.5 nm; ¹H NMR (CDCl₂): δ 8.74 (s, 1H, H-2); 8.46 (s, 1H, H-8); 8.09 (d, 2H, Ar-H, J = 7.4 Hz); 7.59 (t, 1H, Ar-H, J = 7.7 Hz); 7.46 (t, 2H, Ar-H, J= 7.6 Hz; 6.44 (dd, 1H, H-1', J = 19.7 and 2.6 Hz); 5.25 (dm, 1H, H-2', J = 53.5 Hz); 4.65 (m, 3H, H-4' and H-5'); 2.86-2.48 (m, 2H, H-3'); 13 C NMR (CDCl₃) δ 165.3, 151.1, 151.0, 150.1, 143.6, 143.5, 132.4, 128.7, 128.4, 126.1, 90.0 (d, J = 181.0 Hz), 84.4 (d, J = 11.0 Hz), 74.59, 64.55, 32.7 (d, J = 20.0 Hz); Anal. Calcd. for $C_{17}H_{14}ClFN_4O_3\cdot 0.25H_2O$: C, 53.55; H, 3.81; N, 14.69. Found: C, 53.61; H, 3.90; N, 14.69. **43**: mp 106-108 °C; $[\alpha]_D^{25}$ -2.0° (c 0.90, CHCl₃); UV (MeOH) λ_{max} 264.0 nm; IR (KBr) 1720, 1718, 1560, 1070 cm⁻¹; ¹H NMR (CDCl₃): δ 8.76 (s, 1H, H-2); 8.22 (s, 1H, H-8); 8.08 (d, 2H, Ar-H, J = 8.0 Hz); 7.57 (t, 1H, Ar-H, J = 7.4 Hz); 7.46 (t, 2H, Ar-H, J = 8.0 Hz); 6.40 (d, 1H, H-1', J = 12.0 Hz); 5.95 (dd, 1H, H-2', J $(MH)^+$; ¹H NMR (DMSO- d_8): δ 8.14 (s, 1H, H-2); 8.25 (d, 1H, H-8, J = 3.0 Hz); 7.33 (bs, 1H, NH, D_2O exch.); 6.30 (dd, 1H, H-1', J = 16.1 and 3.8 Hz); 5.42 (dm, 1H, H-2', J = 54.5 Hz);

5.05 (t, 1H, 5'-OH, J = 5.5 Hz); 4.16 (m, 1H, H-4'); 3.59 (m, 2H, H-5'); 2.61-2.14 (m, 2H, H-3'); 13 C NMR (DMSO- d_{δ}) δ 157.0, 148.2, 146.6, 139.3, 123.9, 91.6 (d, J = 187.0 Hz), 84.1 (d, J = 16.5 Hz), 78.3, 63.0, 32.4 (d, J = 19.5 Hz); Anal. Calcd. for $C_{10}H_{11}FN_4O_3$: C, 47.20; H, 4.33; N, 21.93. Found: C, 47.32; H, 4.33; N, 21.93.

- **9-(2,3-Dideoxy-2-fluoro-α-L-***threo***-pentofuranosyl)hypoxanthine** (47). A mixture of 43 (0.47 g, 1.13 mmol), 2-mercaptoethanol (0.32 mL, 4.56 mmol), and NaOMe (0.25 g, 4.62 mmol) in MeOH (60 mL) was refluxed for 5 h. The reaction mixture was worked up and purified as described for compound 46 to obtain 47 (0.22 g, 76%) as white crystals. mp 230-232 °C; $[\alpha]_D^{25}$ -55.0° (c 0.57, H₂O); UV (H₂O) λ_{max} 248.5 nm (ε 10800) (pH 2); 248.5 nm (ε 10800) (pH 7); 253.5 nm (ε 11700) (pH 11); IR (KBr) 3273, 1711, 1674 cm⁻¹; MS (ESI) *m/e* 255 (MH)⁺; ¹H NMR (DMSO- d_6): δ 8.26 (s, 1H, H-8); 8.17 (s, 1H, H-2); 7.34 (s, 1H, NH, D₂O exch.); 6.34 (d, 1H, H-1', J = 15.9 Hz); 5.81 (dd, 1H, H-2', J = 52.9 and 4.2 Hz); 5.02 (bs, 1H, 5'-OH. D₂O exch.); 4.57-4.54 (m, 1H, H-4'); 3.53-3.52 (m, 2H, H-5'); 2.86-2.71 and 2.21-2.10 (m, 2H, H-3'); ¹³C NMR (DMSO- d_6) δ 156.8, 147.8, 146.4, 138.7, 124.9, 96.7 (d, J = 178.7 Hz). 89.2 (d, J = 35.3 Hz), 82.2, 63.6, 33.0 (d, J = 19.8 Hz); *Anal.* Calcd. for C₁₀H₁₁FN₄O₃: C, 47.27; H, 4.32; N, 22.04. Found: C, 47.02; H, 4.27; N, 21.90.
- **9-(2,3-Dideoxy-2-fluoro-**β-L-*threo*-pentofuranosyl)adenine (**48**). A solution of **42** (0.08 g, 0.26 mmol) in sat methanolic ammonia (30 mL) was heated at 100 °C in a steel bomb for 20 h. The solvent was evaporated and the residue was purified by silica gel column chromatography (10% MeOH/CHCl₃) to give a white solid **48** (0.05 g, 70%). mp 225-226 °C; $[\alpha]_D^{25}$ -94.6° (c 0.11, MeOH); UV (H₂O) λ_{max} 258.9 nm (ε 12700) (pH 2); 258.5 nm (ε 13600) (pH 7); 258.0 nm (ε 12200) (pH 11); ¹H NMR (DMSO- d_6): δ 8.14 (s, 1H, H-2); 8.25 (d. 1H.H-8, J = 3.0 Hz); 7.33 (bs, 2H, NH₂, D₂O exch.); 6.30 (dd, 1H, H-1', J = 3.8 and 16.1 Hz); 5.42 (dm, 1H, H-2', J = 54.5 Hz); 5.05 (t, 1H, OH, J = 5.5 Hz, D₂O exch.); 4.16 (m, 1H, H-4'); 3.65-3.59 (m, 2H, H-5'); 2.14-2.61 (m, 2H, H-3'); ¹³C NMR (DMSO- d_6) δ 155.3, 153.1, 149.1, 139.3, 118.6, 91.7 (d, J = 181.2 Hz), 83.9 (d, J = 16.5 Hz), 78.2, 63.0, 32.7 (d, J = 19.5 Hz); *Anal.* Calcd. for C₁₀H₁₂N₅O₂·0.25H₂O: C, 46.60; H, 4.88; N, 27.17. Found: C, 46.80; H, 4.78; N, 27.03.
- **9-(2,3-Dideoxy-2-fluoro-α-L-***threo***-pentofuranosyl)adenine (49).** A solution of **43** (0.15 g, 4.00 mmol) in sat methanolic ammonia (30 mL) was heated at 100 °C in a steel bomb for 20 h. The solvent was evaporated and the residue was purified by silica gel column chromatography (5% MeOH:CHCl₃) to give a white solid **49** (0.06 g, 57%). mp 60-62 °C; $|\alpha|_D^{25}$ -42.0° (c 0.30, MeOH); UV (H₂O) λ_{max} 256.5 nm (ε 13900) (pH 2); 260.0 nm (ε 14000) (pH 7): 259.5 nm (ε 14000) (pH 11); IR (KBr) 1691, 1647, 1062 cm⁻¹; MS (FAB) *m/e* 254 (MH)⁺; ¹H NMR (CDCl₃): δ 8.26 (s, 1H, H-8); 8.17 (s, 1H, H-2); 7.34 (s, 2H, NH₂, D₂O exch.); 6.34 (d, 1H, H-1', J = 15.8 Hz); 5.80 (dd, 1H, H-2', J = 52.9 and 4.2 Hz); 5.02 (s, 1H, 5'-OH, D₂O exch.); 4.57-4.54 (m, 1H, H-4'); 3.53-3.52 (m, 2H, H-5'); 2.86-2.71 and 2.21-2.10 (m, 2H, H-3'); ¹³C NMR (CDCl₃) δ 156.4, 153.1, 149.1, 139.6, 119.4, 96.6 (d, J = 179.3 Hz), 89.0 (d, J = 35.6 Hz), 82.2, 63.7, 33.4 (d, J = 19.9 Hz); *Anal.* Calcd. for C₁₀H₁₂N₃O₂·0.54MeOH: C, 46.79; H, 5.28; N, 25.89. Found: C, 46.73; H, 5.08; N, 26.01.
- N^6 -methyl-9-(2,3-Dideoxy-2-fluoro-β-L-threo-pentofuranosyl)adenine (50). A solution of 42 (0.30 g, 0.79 mmol) and methylamine (40% solution in H₂O, 20 mL) in MeOH (20 mL) was heated at 90 °C in a steel bomb for 15 h. After cooling, the solvents were removed under vacuum. The residue was purified by preparative TLC (7% MeOH:CHCl₃) to give 50 (0.15 g, 77%). mp 58-60 °C; [α]_D²⁵ -40.2° (c 0.23, MeOH); UV (H₂O) λ_{max} 261.5 nm (ε 14200) (pH 2);

265.0 nm (£ 13400) (pH 7); 264.5 nm (£ 12900) (pH 11); IR (KBr) 3385, 1628, 1070 cm⁻¹; MS (EI) m/e 268.0 (MH)⁺; ¹H NMR (DMSO- d_6): δ 8.27 (s, 1H, H-8); 8.26 (s, 1H, H-2); 7.84 (s, 1H, NH); 6.33 (dd, 1H, H-1', J = 16.0 and 3.9 Hz); 5.43 (dm, 1H, H-2', J = 58.3 Hz); 5.07 (s, 1H, 5'-OH, D₂O exch.); 4.20-4.14 (m, 1H, H-4'); 3.65-3.56 (m, 2H, H-5'); 2.95 (s, 3H, CH₃); 2.63-2.50 and 2.32-2.19 (m, 2H, H-3'); ¹³C NMR (DMSO- d_6) δ 155.2, 153.1, 148.3, 139.6, 119.0, 91.6 (d, J = 187.2 Hz), 83.9 (d, J = 16.5 Hz), 78.1, 63.1, 32.5 (d, J = 19.5 Hz), 27.3; Anal. Calcd. for C₁₁H₁₄FN₅O₂·0.5MeOH: C, 48.76; H, 5.69; N, 24.72. Found: C, 48.97; H, 5.55; N, 24.70.

*N*⁶-methyl-9-(2,3-Dideoxy-2-fluoro-α-L-threo-pentofuranosyl)adenine (51). A solution of **43** (0.20 g, 0.53 mmol) and methylamine (40% solution in H₂O, 15 mL) in MeOH (15 mL) was heated at 90 °C in a steel bomb for 15 h. After cooling, the solvents were removed under vacuum. The residue was purified by preparative TLC (7% MeOH:CHCl₃) to give **51** (0.10 g, 74%). mp 42-43 °C; [α]_D²⁵ -35.2° (c 0.30, MeOH); UV (H₂O) λ_{max} 262.0 nm (ε 15800) (pH 2); 265.5 nm (ε 12000) (pH 7); 265.5 nm (ε 15000) (pH 11); IR (KBr) 3372, 1630, 1072 cm⁻¹; MS (EI) *m/e* 268.0 (MH⁺); ¹H NMR (DMSO- d_6): δ 8.74 (s, 2H, H-8 and H-2); 8.32 (s, 1H, NH₂, D₂O exch.); 6.84 (d, 1H, H-1', J = 15.6 Hz); 6.29 (dd, 1H, H-2', J = 52.8 and 4.8 Hz); 5.46 (t, 1H, 5'-OH, J = 5.6 Hz, D₂O exch.); 5.07-5.033 (m, 1H, H-4'); 4.05-3.96 (m, 2H, H-5'); 3.45 (s, 3H, CH₃); 3.33-3.24 and 2.70-2.62 (m, 2H, H-3'); ¹³C NMR (DMSO- d_6) δ 155.3, 155.1, 148.0, 139.3, 119.8, 96.5 (d, J = 179.6 Hz), 89.0 (d, J = 35.6 Hz), 82.1, 63.6, 33.2 (d, J = 20.2 Hz), 27.3; *Anal.* Calcd. for C₁₁H₁₄FN₅O₂·0.5H₂O·0.1EtOAc: C, 48.06; H, 5.54; N, 24.57. Found: C, 48.08; H, 5.56; N, 24.28.

9-(2,3-Dideoxy-2-fluoro-β-L-threo-pentofuranosyl)guanine (52). A mixture of 44 (0.15 g, 0.32 mmol), 2-mercaptoethanol (0.2 mL, 2.35 mmol) and NaOMe (0.05 g, 0.92 mmol) in methanol (20 mL) was refluxed for 24 h under nitrogen. The reaction mixture was cooled neutralized with glacial HOAc, and evaporated to dryness under vacuum. The residue was taken up in hot methanol, filtered, washed with H₂O, and triturated in a mixture of MeOH and CHCl₂ (1:1) to give **52** (0.04 g, 45%) as a white foam. mp >300 °C; $[\alpha]_D^{25}$ -14.1° (c 0.47, DMSO); UV $(H_2O) \lambda_{max} 253.5 \text{ nm} (\epsilon 6520) (pH 2); 251.0 \text{ nm} (\epsilon 7130) (pH 7); 256.5 \text{ nm} (\epsilon 5720); IR (KBr)$ 3427, 1693 cm⁻¹; HRMS (FAB): calculated m/e 270.1002. Found: 270.1007 (MH)⁺; ¹H NMR (DMSO- d_6): δ 11.00 (s, 1H, NH); 7.76 (d, 1H, H-8, J = 2.3 Hz); 6.75 (s, 2H, NH₂, D₂O exch.); 5.98 (dd, 1H, H-1', J = 16.5 and 3.8 Hz); 5.34 (dm, 1H, H-2', J = 54.3 Hz); 5.01 (s, 1H, 5'-OH, D₂O exch.); 4.12-4,06 (m, 1H, H-4'); 3.61-3.54 (m, 2H, H-5'); 2.59-2.43 and 2.24-2.12 (m, 2H, H-3'); ¹³C NMR (DMSO- d_s) δ 155.7, 151.4, 135.7, 132.9, 116.3, 91.5 (d, J = 186.1Hz), 83.3 (d, J = 16.3 Hz), 77.7, 63.2, 32.7 (d, J = 19.4 Hz); Anal. Calcd. for C₁₀H₁₂FN₅O₃·0.4CHCl₃: C, 39.41; H, 3.94; N, 22.09. Found: C, 39.41; H, 4.21; N, 22.15. 9-(2,3-Dideoxy-2-fluoro-α-L-threo-pentofuranosyl)guanine (53). A mixture of 45 (0.22 g, 0.47 mmol), 2-mercaptoethanol (0.2 mL, 2.35 mmol) and NaOMe (0.06 g, 1.11 mmol) in methanol (30 mL) was refluxed for 16 h under nitrogen. The reaction mixture was cooled neutralized with glacial HOAc, and evaporated to dryness under vacuum. The residue was taken up in hot methanol, filtered, washed with H₂O, and crystallized in MeOH to give 53 (0.06 g, 57%) as white crystals. mp >300 °C; $[\alpha]_D^{25}$ -52.6° (c 0.27, DMSO); UV (H₂O) λ_{max} 255.5 nm (ϵ 12500) (pH 2); 251.5 nm (ε 13100) (pH 7); 262.0 nm (ε 15800) (pH 11); IR (KBr) 3182, 1701, 1072 cm⁻¹; MS (FAB) m/e 270 (MH)⁺; ¹H NMR (DMSO- d_6): δ 10.67 (s, 1H, NH); 7.62 (s, 1H, H-8); 7.02 (s, 2H, NH₂); 6.09 (d, 1H, H-1', J = 16.03 Hz); 5.66 (dd, 1H, H-2', J = 52.8 and 4.8 Hz); 4.93 (s, 1H, 5'-OH, D,O exch.); 4.50-4.44 (m, 1H, H-4'); 3.51-3.39 (m, 2H, H-5');

2.81-2.00 (m, 2H, H-3'); ¹³C NMR (DMSO- d_6) δ 163.2, 158.4, 151.4, 134.1, 117.4, 96.7 (d, J = 177.5 Hz), 88.3 (d, J = 34.5 Hz), 81.7, 63.8, 33.3 (d, J = 20.3 Hz); *Anal.* Calcd. for $C_{10}H_{12}FN_5O_3$; C, 44.60; H, 4.40; N, 26.00. Found: C, 44.53; H, 4.48; N, 26.08.

ACKNOWLEDGMENTS

We thank Dr. Michael Bartlett for providing the mass spectral analysis data. We acknowledge the financial support of the NIH grants # AI32351 and AI33655 and the Department of Veterans Affairs.

REFERENCES

- Chang, C. N., Doong, S. L., Zhou, J. H., Beach, J. W., Jeong, L. S., Chu, C. K., Tsai, C. H., Cheng, Y.-C., Liotta, D. and Schinazi, R. J. Biol. Chem. 1992 267, 13938-13942.
- 2. Belleau, B., Dixit, D., Nguyen-Ga, N. and Kraus, J.-L. 1990, 515.
- Furman, P. A., Davis, M., Liotta, D. C., Paff, M., Frick, L. W., Nelson, D. J..
 Dornsife, R. E., Wurster, J. A., Wilson, L. J., Fyfe, J. A., Tuttle, J. V., Miller, W. H.,
 Condreay, L., Avereet, D. R., Schinazi, R. F. and Painter, G. R. Antimicrob. Agents
 Chemother. 1992 36, 2686-2692.
- 4. Schinazi, R. F., Gosselin, G., Faraj, A., Korba, B. E., Liotta, D. C., Chu, C. K., Mathe, C., Imbach, J.-L. and Sommadossi, J.-P. *Antimicrob. Agents Chemother.* 1994 38, 2172-2174.
- Coates, J. A., Cammack, N. S., Jenkinson, H. J., Jowett, M. I., Pearson, B. A., Penn, C. R., Rouse, P. L., Viner, K. C. and Cameron, J. M. Antimicrob. Agents Chemother. 1992 36, 733-739.
- Doong, S. L., Tsai, C. H., Scinazi, R. F., Liotta, D. C. and Cheng, Y.-C. *Proc. Natl. Acad. Sci. U.S.A.* 1991 88, 8495-8499.
- 7. Chang, C. N., Skalski, V., Zhou, J. H. and Cheng, Y.-C. J. Biol. Chem. 1992 267, 22414-22420.
- 8. Grove, K. L., Guo, X., Liu, S. H., Gao, Z., Chu, C. K. and Cheng, Y.-C. Cancer Res. 1995 55, 3008-3011.
- 9. Pai, S. B., Liu, S. H., Zhu, Y. L., Chu, C. K. and Cheng, Y.-C. Antimicrob. Agents Chemother. 1996 40, 380-386.
- Pelicano, H., Pierra, C., Eriksson, S., Gosselin, G., Imbach, J.-L. and Maury, G. J. Med. Chem. 1997 40, 3969-3973.
- Kim, H. O., Shanmuganathan, K., Alves, A. J., Jeong, L. S., Beach, J. W., Schinazi, R. F., Chang, C. N., Cheng, Y.-C. and Chu, C. K. Tetrahedron Lett. 1992 33, 6899-6902.
- Kim, H. O., Schinazi, R. F., Shanmuganathan, K., Jeong, L. S., Beach, J. W.,
 Nampalli, S., Cannon, D. L. and Chu, C. K. J. Med. Chem. 1993 36, 519-528.
- Chu, C. K., Ma, T., Shanmuganathan, K., Wang, C., Xiang, Y., Pai, S. B., Yao, G. Q., Sommadossi, J.-P. and Cheng, Y.-C. Antimicrob. Agents Chemother. 1995 39, 979-981.
- Wright, J. D., Ma, T. W., Chu, C. K. and Boudinot, F. D. Pharm. Res. 1995 12, 1350-1353.

 Lin, T. S., Luo, M. Z., Liu, M. C., Pai, S. B., Dutschman, G. E. and Cheng, Y.-C. J. Med. Chem. 1994 37, 798-803.

- Gosselin, G., Schinazi, R. F., Sommadossi, J.-P., Mathe, C., Bergone, M. C., Aubertin, A. M., Kirn, A. and Imbach, J.-L. Antimicrob. Agents Chemother. 1994 38, 1292-1297.
- Marquez, V. E., Tseng, C. K., Mitsuya, H., Aoki, S., Kelly, J. A., Ford, H. J., Roth, J. S., Broder, S., John, D. G. and Driscoll, J. S. J. Med. Chem. 1990 33, 978-985.
- Siddiqui, M. A., Driscoll, J. S., Marquez, V. E., Roth, J. S., Shirasaka, T., Mitsuya, H., Barchi, J. J. J. and Kelley, J. A. J. Med. Chem. 1992 35, 2195-2201.
- Xiang, Y., Cavalcanti, S., Chu, C. K., Schinazi, R. F., Pai, S. B., Zhu, Y. L. and Cheng, Y.-C. *Bioorg. & Med. Chem. Lett.* 1995 5, 877-880.
- Misra, S., Jain, S., Avasthi, K. and Bhakuni, D. S. Nucleosides & Nucleotides 1990 9, 837-846.
- Ma, T., Pai, B., Zhu, Y. L., Lin, J. S., Shanmuganathan, K., Du, J., Wang, C., Kim, H., Newton, G., Cheng, Y.-C. and Chu, C. K. J. Med. Chem. 1996 39, 2835-2843.
- 22. Nair, V. and Sinhababu, A. K. J. Org. Chem. 1977 43, 5013-5017.
- Shanmuganathan, K., Koudriakova, T., Nampalli, S., Du, J., Gallo, J. M., Schinazi, R. F. and Chu, C. K. J. Med. Chem. 1994 37, 821-827.
- 24. Townsend, L. B. Chemistry of Nucleosides and Nucleotides; Plenum Press: New York, 1988; Vol. 1.
- 25. Collorless prism crystal of orthorhombic system with the lattice parameters: a = 8.812 Å, b = 11.159 Å, c = 16.392 Å, V = 1611.984; space group P212121.

Received 12/14/98 Accepted 7/16/99